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Abstract 
 
Previously, acyl derivatives of CoA were shown to antagonise 
human native and recombinant P2Y1 purine receptors. The main 
aim of this thesis was to study the effect of these endogenous 
nucleotide derivatives at endogenous P2Y1 receptors in blood 
vessels. Using isometric tension recordings, CoA, acetyl-CoA and 
palmitoyl-CoA (PaCoA) appeared to show selectivity for P2Y1 
receptors (over P2Y2 and adenosine receptors) in the rat isolated 
thoracic aorta, with PaCoA being the most potent of the CoA 
derivatives used.  
In porcine isolated mesenteric arteries (PMA) and porcine 
isolated coronary arteries (PCA), isometric tension recordings 
indicated that ADP mediated endothelium-dependent and 
endothelium-independent relaxations, respectively. Relaxations 
in PMA were blocked by the P2Y1 receptor antagonist MRS2500 
and PaCoA, whilst these were ineffective against ADP relaxations 
in the PCA.  
A FlexStation was used to monitor calcium responses in native 
HEK293 cells expressing P2Y1 and P2Y2 receptors using ADP 
and UTP, respectively. Responses to UTP were not significantly 
altered in the presence of PaCoA. In contrast, ADP-evoked 
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responses were significantly inhibited in the presence of either 
MRS2500 or PaCoA.  
These data raise the possibility of an endogenous selective 
antagonism of P2Y1 receptors via CoA compounds, irrespective 
of species or cellular environment.   
 
Nicotinamide adenine dinucleotide (NAD) is an intracellular 
nucleotide which has been identified as an agonist at P2Y1, 
P2Y11, P2X and adenosine receptors. NAD evoked endothelium-
independent concentration-dependent contractions of the pre-
contracted PMA, which were unaltered in the presence of PaCoA. 
,Q FRQWUDVW ǂǃ-methylene ATP (a desensitizing P2X receptor 
agonist) significantly reduced these responses suggesting the 
involvement of P2X1-like receptors. 
 
In both RTA and PCA, NAD evoked endothelium-independent 
concentration-dependent relaxations of the pre-contracted 
vessels, which were attenuated by SCH58261, but not PaCoA, 
which suggests the involvement of smooth muscle A2A receptors. 
These results together emphasise the possibility of a tissue and 
receptor-specific role of NAD as an endogenous extracellular 
nucleotide in purinergic signalling. 
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1.1  A Brief Historical Introduction 
 
It was in 1929 when the extracellular signalling function of purine 
nucleotides and nucleosides was first recognized, with the report of 
Drury and Szent-Gyorgi, who showed that adenosine and adenosine ·-
monophosphate (AMP) can have potent physiological effects such as 
slowing the heart rate, dilatation of the coronary vessels and inhibition 
of intestinal movements (Drury and Szent-Gyorgyi, 1929). This 
aroused interest in this group of compounds and the work was 
extended by a study of the structure-activity relationships of adenine 
compounds by Gillespie. He showed amongst other things that the 
removal of phosphate from AMP does not lessen its activity so 
markedly as deamination and that the biological activity disappears 
from the compounds when the pentose is split from the purine base 
(Gillespie, 1934). 
 
A number of other studies followed, showing diverse effects of purines 
on the cardiovascular system and were reviewed in 1950 (Green and 
Stoner, 1950). In 1959, Holton was the first to present a role for ATP 
as a transmitter in the nervous system by demonstrating its release 
during antidromic stimulation of sensory nerves supplying the rabbit 
ear artery (Holton, 1959) 
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The interest in this family of compounds expanded to include the 
pyrimidine nucleotides through investigation of the cardiovascular 
effects of uridine triphosphate (UTP), with these early studies showing 
that purines and pyrimidines have characteristic vascular activity 
(Hashimoto et al., 1964, Sakai et al., 1979). 
 
6HYHUDO SXULQH GLQXFOHRWLGHV VXFK DV ǃ-nicotinamide adenine 
dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate 
(NADP) have also been shown to have potent actions on diverse 
tissues. NAD was recently shown to be released in a variety of smooth 
muscle tissues during stimulation of sympathetic nerves terminals in 
canine isolated mesenteric artery, blood vessels, urinary bladder and 
murine colonic muscles and was described as a neurotransmitter or 
neuromodulator (Smyth et al., 2004, Smyth et al., 2006, Breen et al., 
2006, Mutafova-Yambolieva et al., 2007).  
 
In 1957 Boettge published an extensive review describing the 
physiological and pharmacological significance of adenyl compounds in 
humans (Boettge et al., 1957). This was followed by a hypothesis 
proposed in 1963 by Berne, which suggested that adenosine was the 
physiological mediator of the coronary vasodilatation associated with 
myocardial hypoxia (Berne, 1963). Burnstock presented an alternative 
hypothesis that ATP released from endothelial cells acts via endothelial 
P2 receptors to cause a release of nitric oxide (NO) which results in 
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vasodilatation, and that adenosine is involved only in the longer-lasting 
component of reactive hyperaemia (Burnstock, 1993). 
 
It was in the early 1960s that non-adrenergic, non-cholinergic (NANC) 
neurotransmission was first noticed and many studies were carried out 
in order to try to identify the nature of this response in different tissues 
such as guinea-pig taenia Coli (Burnstock et al., 1963, Burnstock et al., 
1964, Burnstock et al., 1966, Martinson and Mauren, 1963). Evidence 
was presented that ATP was the molecule released from NANC nerves and 
responsible for NANC neurotransmission. This was followed later with the 
proposal of WKHWHUP¶SXULQHUJLF·VWDWLQJWKDWDGHQRVLQHWULSKRVSKDWHRr a 
related nucleotide is the transmitter involved in NANC and sympathetic 
neurotransmission in a wide variety of systems (Burnstock et al., 1970, 
Burnstock et al., 1972, Burnstock, 1972). 
 
The purinergic hypothesis met with huge resistance from many 
scientists since ATP was considered unlikely to have this role as an 
extracellular signalling molecule. ATP was known as an intracellular 
molecule and source of energy involved in a variety of metabolic cycles 
(Burnstock, 2006). It was almost 25 years later that the purinergic 
hypothesis became widely accepted (Burnstock, 1997). 
 
Purinergic receptors were first introduced by Burnstock in 1976 
(Burnstock, 1976). In 1978, he set the basis for distinguishing two types 
of purinoceptors. He suggested that these receptors should be classified 
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into two different types; P1 purinoceptors, at which adenosine is the 
primary ligand, and P2 purinoceptors, at which ATP and ADP are the 
principal ligands (Burnstock, 1978). P2 receptors are now known to be 
activated also by UTP, UDP, UDP-glucose and other nucleotide sugars. 
Both P1 and P2 receptors may involved in physiological responses to ATP 
and ADP since adenosine can be derived from them in metabolic 
breakdown. 
 
P1 and P2 receptors for purines and pyrimidines are now known to be 
expressed in a wide range of biological systems including the central 
and peripheral nervous systems, respiratory, gastrointestinal and 
cardiovascular systems and mediate a variety of diverse effects 
including regulation of contractility, neurotransmission, immune 
function and cell migration and proliferation. 
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1.2  Purine Receptors 
1.2.1  P1 Receptors 
 
Four subdivisions of P1 receptors have been identified; namely A1, A2A, 
A2B and A3 (Table 1). All P1 receptors are G protein-coupled receptors 
with 7 transmembrane domains which are connected by extracellular and 
intracellular hydrophilic loops. The seven transmembrane domains are 
composed of hydrophobic amino acids, each having 21-28 amino acids 
combining together to IRUPDQǂ-helix, with the N-terminal lying on the 
extracellular side and the C²terminal lying on the intracellular side of the 
membrane (Ralevic and Burnstock, 1998). Their signal transduction 
mechanism is through multiple intracellular effectors in response to 
nucleoside activation. The main distribution, agonists, antagonists and 
G-protein coupling for each subtype is shown in Table 1. 
 
1.2.2  P2 Receptors 
 
P2 receptors are divided into two classes based on whether they are 
ligand-gated ion channels, named P2X receptors (ionotropic), or are 
coupled to G proteins, named P2Y receptors (metabotropic). This was  
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based on studies of the mechanisms of signal transduction and the 
cloning of receptors (Abbracchio and Burnstock, 1994, Fredholm et 
al., 1994) (Table 1). Unfortunately, pharmacological characterisation of 
endogenous P2 receptors is limited by overlap in their agonist 
selectivities, general lack of selective antagonists and metabolic 
interaction of nucleosides and nucleotides. 
 
Studies of native P2 receptors had shown significant heterogeneity in 
the pharmacological responses indicating the presence of different 
subtypes of P2 receptor. To date, there are seven subtypes of the P2X 
(P2X1²7) family and eight subtypes of the P2Y (P2Y1,2,4,6,11,12,13,14) family; 
the missing numbers represent either receptors having partial 
sequence homology to P2Y receptors but having no functional 
evidence of activation by nucleotides, or they are non-mammalian 
orthologues. The cloning of the first two P2 receptors, P2Y1 and P2Y2 
provided the basis for a revision in receptor nomenclature and a basis 
on which to identify native P2 receptor subtypes (Webb et al., 1993, 
Lustig et al., 1993). The P2Y12 receptor found principally on platelets 
was not cloned until more recently (Hollopeter et al., 2001); it has only 
19% homology with the other P2Y receptor subtypes hence it was 
proposed that it represented one of a subgroup of P2Y receptors, 
including P2Y13 and P2Y14; for this subgroup signal transduction is 
entirely through adenylate cyclase (Abbracchio et al., 2003). Therefore 
it has been suggested that P2Y receptors can be subdivided into two 
subgroups; one that includes P2Y1,2,4,6,11, the other includes P2Y12,13,14; 
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this largely depends on the structural and phylogenetic criteria 
(Abbracchio et al., 2003). 
 
1.2.2.1  P2X Receptors  
 
There are seven P2X receptor subtypes (P2X1-7) that have been cloned. 
P2X receptors are ATP-gated ion channels that mediate rapid and 
selective permeability to cations; Na+, K+ and Ca2+ (North, 1996, Bean, 
1992, Dubyak and el-Moatassim, 1993). This goes with their role as 
mediators of fast excitatory neurotransmission to ATP in the central 
and peripheral nervous systems. The receptor subunits are composed 
of two transmembrane domains, an extracellular loop and two 
intracellular domains. The extracellular loop is composed of 10 
cysteine residues, 14 glycine residues and 2-6 N-linked glycosylation 
sites. The extracellular loop contains the ATP binding site (Jiang et al., 
2000) and a site where a potential antagonist can bind (Garcia-
Guzman et al., 1997). It has a hydrophobic H5 region that is located 
on the entrance to the pore. This area could have a role in the 
regulation and modulation of the channel through various ions such 
as Cu2+, Ca2+, Mg2+ and Zn2+. Disulfide bridges may form the 
structural constraints needed to couple the ATP-binding site to the ion 
pore. 
 
1: General Introduction  
 
8 
 
The subunits of the P2X receptors can be homomeric (composed of 
identical subunits) or heteromeric (composed of different subunits) and 
their properties vary with each individual subunit. For example it has 
been shown that P2X2 and P2X3 proteins can combine to form a 
functional P2X2/3 heteromeric receptor (Lewis et al., 1995, Ralevic and 
Burnstock, 1998, Radford et al., 1997). Functional P2X receptors appear 
to be composed of three subunits (Stoop et al., 1999, Nicke et al., 1998, 
Jiang et al., 2003). The signal transduction mechanisms for the receptor 
seem to start after the activation of the P2X receptor where a rapid 
nonselective passage of cations (Na+, Ca2+, K+) crosses the cell membrane 
which results in the generation of excitatory junction potentials and an 
increase in Ca2+ levels inside the cell ending in membrane depolarisation 
(Bean, 1992). If this depolarisation reaches a threshold it will lead to the 
activation of L-type voltage gated Ca2+ channels in addition to calcium-
stimulated tyrosine kinases which activate MAP kinases that modulate 
transcriptional processing (Boarder and Webb, 2001a). P2X receptors are 
located in various tissues in the body; smooth muscle cells, nerves, 
endothelial cells in blood vessels, immune cells, glands and glial cells. 
Table 1.1 shows the main distribution, agonists, antagonists and signal 
transduction mechanism for each subtype of P1 and P2 receptor. 
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Table 1.1 Characteristics of purine-regulated receptors. 
Receptor Main Distribution Selective agonists 
Selective 
antagonists 
Principle 
transduction  
P1 
(adenosine)         
A1 Brain, spinal cord, 
testis, heart, 
autonomic nerve 
terminals 
CPA, CCPA, S-
ENBA, 
PSB36, DPCPX, Gi/o   
GR79236 SLV320 
A2A Brain, heart, 
lungs, spleen, 
blood vessels 
CGS21680, 
HENECA, 
SCH58261, 
ZM241385, KW 
6002 SCH442416 
GS  
ATL-146e 
A2B Large intestine, 
bladder, blood 
vessels 
Bay60-6583 PSB603 , 
MRS1754, 
MRS1706, 
GS   
PSB1115  
A3 Lung, liver, brain, 
testis, heart 
2-Cl-IB-MECA, IB-
MECA 
MRS1220, 
VUF5574, 
MRS1523, 
MRS1191  
Gi/o 
P2X 
        
P2X1 Smooth muscle, 
platelets, 
cerebellum, dorsal 
horn spinal 
neurons 
L-ȕȖ-PH$73Įȕ-
meATP, 
TNP-ATP (non- 
slelective), IP5I, 
NF023, NF449 
Intrinsic 
cation 
channel (Ca2+ 
and Na+) 
BzATP 
P2X2 Smooth muscle, 
CNS, retina, 
chromaffin cells, 
autonomic and 
sensory ganglia 
- - Intrinsic ion 
channel 
(particularly 
Ca2+) 
P2X3 Sensory neurons, 
NTS, some 
sympathetic 
neurons 
Įȕ-meATP, BzATP TNP-ATP (non-
selective), 
Intrinsic 
cation 
channel 
A317491, RO3 
P2X4 CNS, testis, colon - - Intrinsic ion 
channel 
(especially 
Ca2+) 
P2X5 Proliferating cells 
in skin, gut, 
bladder, thymus, 
spinal cord 
- - Intrinsic ion 
channel 
P2X6 CNS, motor 
neurons in spinal 
cord 
- - Intrinsic ion 
channel 
P2X7 Apoptotic cells in, 
for example, 
immune cells, 
pancreas, skin 
- Brilliant Blue G, 
A804598, 
A839977, 
Intrinsic 
cation 
channel and 
a large pore 
with 
prolonged 
activation 
decavanadate, 
KN62, A740003, 
A438079 
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P2Y         
P2Y1 Epithelial and 
endothelial cells, 
platelets, immune 
cells, osteoclasts 
2-MeSADP, 
$'3ȕ6 
MRS2179, 
MRS2500, 
MRS2279, PIT 
Gq/11 
MRS2365  
P2Y2 Immune cells, 
epithelial and 
endothelial cells, 
kidney tubules, 
osteoblasts 
2-thio-UTP, 
UTP S, Ap4A  
- Gq/11 
P2Y4 Endothelial cells UTP S ATP Gq/11 
P2Y6 Some epithelial 
cells, placenta, T 
cells, thymus 
3-Phenacyl-UDP, 
UDP 
MRS2578 Gq/11 
      MRS2567    
P2Y11 Spleen, intestine, 
granulocytes 
ARC67085, NAD, 
NAADP, 
NF157 Gs, Gq/11 
P2Y12 Platelets, glial 
cells 
ADP, 2-MeSADP ATP, ARL66096 Gi/o 
          
P2Y13 Spleen, brain, 
lymph nodes, 
bone marrow 
- MRS2211 Gi/o 
P2Y14 Placenta, adipose 
tissue, stomach, 
intestine, discrete 
brain regions 
MRS2690 - Gi/o 
 
Shown are receptor subtypes for purines and pyrimidines: distribution, agonists, 
antagonists, and transduction mechanisms. BBG, Brilliant blue green; BzATP 2·- & 3·-
O-(4-benzoyl-benzoyl)-ATP; CCPA, chlorocyclopentyl adenosine; CPA, 
cyclopentyladenosine; CTP, cytosine triphosphate; IP3, inosine triphosphate; Ip5I, di-
inosine pentaphosphate; 2-MeSADP, 2-methylthio ADP; 2-MeSATP, 2-methylthio ATP; 
NECA, 5·-Nethylcarboxamido adenosine; PLC, phospholipase C; RB2, Reactive blue 2. 
P2X receptor subtype agonist potencies are based on rat preparations, while P1 and 
P2Y receptor subtype agonist potencies are based on human preparations. Adapted 
from (Burnstock, 2007). 
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1.2.2.2  P2Y Receptors 
 
P2Y receptors are G protein-coupled receptors composed of 308-377 
amino acids. They have seven transmembrane domains with 
hydrophilic loops connecting them on the extracellular and 
intracellular sides, they have an extracellular N terminus and 
intracellular C terminus which has binding sites for protein kinases. 
There are great levels of homology in the transmembrane-spanning 
region sequences but there is a great structural diversity in the 
intracellular loops and the C terminus between the subtypes which 
leads to a variation in the extent of G protein coupling. Stoichiometric 
investigation of this receptor have indicated that the P2Y1 receptor is 
able to heterodimerise with the A1 receptor (Yoshioka et al., 2002). 
 
Primary sequencing of the P2Y1 receptor and the use of the structural 
homologue rhodopsin has characterised positively charged amino acid 
residues in transmembrane regions 3, 6, and 7 that can be involved in 
ligand binding by electrostatic interactions with the phosphates of ATP 
(and presumably ADP) (Van Rhee et al., 1995, Jiang et al., 1997). 
Mutagenesis of the P2Y2 receptor to convert positively charged amino 
acids in transmembrane regions 6 and 7 to neutral amino acids 
causes a 100- to 850-fold decrease in the potency of ATP and UTP,  
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which indicates a role for these amino acids in binding purines and 
pyrimidines (Erb et al., 1995). 
 
P2Y receptors act via G protein coupling. The G proteins can be 
classified according to their sequence homology and function into 4 
families: Gs, Gq/11, Gi/o, G12/13. Each family binds predominantly to 
different second messenger signalling pathways (Neves et al., 2002). 
 
Although most P2Y receptors act via G protein coupling to activate 
phospholipase C (PLC) (Boyer and Harden, 1989), there are examples 
where the P2Y receptor is coupled to the inhibition of adenylyl cyclase 
(Boyer et al., 1996b, Boyer et al., 1993, Webb et al., 1996, Boyer et al., 
1994, Boyer et al., 1995). The activation of PLC can eventually lead to 
the formation of inositol 1,4,5-trisphosphate (IP3) and mobilization of 
intracellular Ca2+ and the activation of other pathways such as protein 
kinase C (PKC), mitogen activated protein kinase pathways, 
phospholipase A2, nitric oxide synthase and calcium dependent 
potassium channels. Since there are second messenger systems 
and/or ionic conductances mediated by G protein coupling, the 
response time of P2Y receptors is longer than that mediated by P2X 
receptors. 
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P2Y purine receptors have a wide distribution and mediate responses 
in various tissues. For example, P2Y receptors are found in different 
regions of kidney glomeruli, tubules and collecting ducts (Eltze and 
Ullrich, 1996, Dockrell et al., 2001, Cuffe et al., 2000, Bailey et al., 
2000, van Der Weyden et al., 2000, Cha et al., 1998, Huber-Lang et 
al., 1997). P2Y receptors are present in the brain, on both presynaptic 
sites and on glial cells (Webb and Barnard, 1999, Zundorf et al., 2001, 
Moran-Jimenez and Matute, 2000, Moore et al., 2000, Schafer and 
Reiser, 1999, Neary et al., 1999). They are also present throughout the 
cardiovascular system. The main distribution of the different subtypes 
of P2Y receptor is shown in Table 1.1. 
 
1.2.2.2.1  P2Y1 Receptors 
P2Y1 receptors were first cloned from chick brain (Webb et al., 1993). 
Table 2 shows the cloned P2Y1 receptors from different species. While 
the  activation of P2Y1 receptors is mostly associated with an increase 
in PLC activity (Boyer and Harden, 1989), there are examples where 
the P2Y1 receptor is coupled to inhibition of adenylyl cyclase activity 
(Boyer et al., 1993, Boyer et al., 1994, Boyer et al., 1995, Boyer et al., 
1996b). Some studies on glioma C6-2B and C6 cells have shown the 
presence of a P2Y1-like receptor that is coupled to the inhibition of 
adenylyl cyclase but is not effective in the activation of inositol 
phosphate accumulation (Schachter et al., 1996, Schachter et al., 
1997a). This resulted in the proposal that two different types of P2Y1-
like receptors exist; one coupled to PLC and another one coupled to 
adenylyl cyclase. Webb et al. (1996) concluded that a single P2Y1 
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receptor may be involved in different signalling pathways in different 
cell types, and that the two pathways do not coincide with each other 
(Webb et al., 1996).  
 
P2Y1 receptors respond to a variety of agonists: adenosine 5·-O-
WKLRGLSKRVSKDWH$'3ǃ62-methylthio-ATP (2MeSATP), 2-methylthio-
ADP (2MeSADP) and ADP all have greater potency than ATP. The P2Y1 
receptor  is more sensitive to adenine nucleotide diphosphates than to 
triphosphates, while uridine di- and triphosphates are inactive (Leon 
et al., 1997, Boarder and Hourani, 1998). In contrast, the P2Y2 
receptor is activated by both ATP and UTP, while 2MeSATP and ADP 
have no effect. P2Y4 and P2Y6 receptors show some selectivity for UTP 
and UDP, respectively, while the P2Y11 receptor is selective for ATP but 
not UTP (Boarder and Hourani, 1998, Nicholas et al., 1996b, Webb et 
al., 1998). NAD also was shown to be an agonist at the P2Y1 receptor 
(Mutafova-Yambolieva et al., 2007).  
 
Heterogeneity in ligand binding at purine receptors includes both 
agonist and antagonists binding profiles. Pyridoxal-phosphate-6-
azophenyl-ĻĻ-disulphonic acid (PPADS) acts as an antagonist at the 
P2Y1 receptor. In contrast, the P2Y2 receptor was shown to have 
species variation in sensitivity to this compound (Rayment et al., 
2007a). Recombinant P2Y1 receptors cloned from different species and 
tissues show different relative potencies to ATP and ADP as do their 
endogenous counterparts (Ralevic and Burnstock, 1998) (Table 1.2). 
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In blood vessels, P2Y1 receptors are found mainly on the endothelium, 
where they cause vasorelaxation through Ca2+-dependent activation of 
endothelial nitric oxide synthase (NOS) and generation of 
endothelium-dependent hyperpolarizing factor (EDHF) (Ralevic and 
Burnstock, 1998) (Figure 1.1). In contrast, contractile P2Y1 receptors 
are expressed in vascular smooth muscle cells (Pacaud et al., 1995, 
Erlinge et al., 1998), since P2Y1 receptors act primarily through 
activation of Gq/11 G-proteins which will lead to the elevation of [Ca2+]i 
and lead to smooth muscle contraction, rather than relaxation. 
 
Although ADP has been shown to produce a direct endothelium-
independent vasodilatation in varius tissues such as rabbit hepatic 
artery and human pulmonary artery, it is not clear whether this 
occurs through the P2Y1 receptor (Kennedy and Burnstock, 1985, 
Brizzolara and Burnstock, 1991, Liu et al., 1989, Burnstock and 
Warland, 1987). A study investigated the mechanism of ADP-induced 
relaxation of porcine coronary artery and suggested that ADP mediates 
relaxation via a novel mechanism that involves adenine nucleotide 
evoked adenosine release and the subsequent activation of A2A 
receptors (Rayment et al., 2007b). NAD has also been reported to 
evoke the release of adenosine in rat vas deferens, guinea-pig taenia 
coli and guinea-pig bladder (Stone, 1981). 
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P2Y1 receptors are colocalized in some cells with P2Y2 receptors; while 
ATP is a common agonist, the receptors may be distinguished as ADP 
is selective for the P2Y1 receptor, and UTP acts only at the P2Y2 
receptor. Endothelial cells express P2Y1 and P2Y2 receptors and may 
express P2Y4 receptors at which UTP is also an agonist (Burnstock, 
2004). It was concluded that more than one subtype of P2Y receptor 
can regulate responses in an individual endothelial cell (Boarder and 
Hourani, 1998). 
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Table 1.2 Cloned P2Y1 receptors. 
 
cDNA library source Agonist activity References 
Human brain 2MeSATP > ATP >> UTP Schachter et al., 1996 
Human prostate and ovary 2MeSATP > ATP = ADP Janssens et al., 1996 
Human placenta ___________ Le´on et al., 1995, 1997 
Human HEL cells ___________ Ayyanathan et al., 1996 
Bovine endothelium 2MeSATP = ADP > ATP >> UTP Henderson et al., 1995 
Rat insulinoma cells 
2MeSATP > 2Cl-$73 ! $73 Įȕ-meATP 
inactive) Tokuyama et al., 1995 
Rat ileal myocytes 
2MeSATP= 2ClATP > ADP >ATP (UTP 
inactive) Pacaud et al., 1996 
Mouse insulinoma cells ____________ Tokuyama et al., 1995 
Turkey brain 2MeSATP > ADP >ATP (UTP inactive) Filtz et al., 1994 
Chick brain 2MeSATP > ATP > ADP (UTP inactive) Webb et al., 1993b 
 
 
Adapted from Ralevic and Burnstock, 1998. 
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,QSDQFUHDWLFǃFHOOV3<1 receptors are involved in insulin secretion 
(Loubatieres-Mariani and Chapal, 1988). P2Y1, P2Y12 and P2X 
receptors have been identified in platelets (Kunapuli and Daniel, 
1998). P2Y1 receptors are present on non-myelinating Schwann cells 
while P2Y2 receptors are found on myelinating Schwann cells (Mayer 
et al., 1998). 
 
P2Y1 and P2Y2 receptors have also been reported to be present on the 
membranes of rat liver isolated mitochondria and it was hypothesized 
that P2Y1 and P2Y2 receptors played a role in internal mitochondrial 
signalling and may contribute to calcium homeostasis (Belous et al., 
2004, Belous et al., 2006). ATP was shown to act intracellularly 
through the mitoKATP channel, ATP-regulated Ca2+ channels and ATP-
dependent anion channels (Belous et al., 2004, Brookes et al., 2004). 
It has also been shown that P2Y1, P2Y2 and P2Y12 receptors are 
present in mitochondria of rat astrocytes and glioma C6 cells 
(Krzeminski et al., 2007). Whether these intracellular P2Y receptors 
contribute to signalling by extracellular ATP has not yet been 
identified. 
 
Desensitization of P2Y1 receptors have been reported to involve 
phosphorylation by protein kinases and uncoupling from the 
associated G protein (Hardy et al., 2005, Rodriguez-Rodriguez et al., 
2009). Studying P2Y1 receptors in turkey erythrocyte membranes 
showed that desensitization with a t1/2 of 15 minutes occured which 
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was heterologous and involved multiple mechanisms, but not PKC or 
intracellular Ca2+ (Galas and Harden, 1995). 
 
1.3 Therapeutic significance of P2Y receptors 
 
It was suggested in several studies that modulators of members of the 
P2Y family of receptors can have therapeutic potential for the 
treatment of a variety of disorders such as cancer, cystic fibrosis, 
diabetes, and treatment of ischemia-reperfusion injury (Abbracchio 
and Burnstock, 1994, Burnstock and Williams, 2000). 
 
For P2Y1 receptors, their distribution and biological effects has 
revealed considerable information about their physiological 
significance. P2Y1 receptors are widely spread among human organs 
(Janssens et al., 1996). They have been identified on microglia 
(Norenberg et al., 1994), and on astrocytes (Salter and Hicks, 1995). 
Extracellular ATP activates microglia and astrocytes through P2Y1 
receptors and leads directly to the release of inflammatory mediators . 
(Fischer and Krugel, 2007) and astrocytes are believed to play a role in 
the progression of Alzheimer's disease and other CNS inflammatory 
disorders like multiple sclerosis and stroke. 
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P2Y1 receptors mediate many other effects including glycogenolysis in 
rat hepatocytes (Keppens and De Wulf, 1991), insulin secretion from 
pancreatic -cells (Bertrand et al., 1987, Hillaire-Buys et al., 1991, 
Hillaire-Buys et al., 1993, Hillaire-Buys et al., 1994), gluconeogenesis 
in renal cortical tubules (Cha et al., 1995), and renin secretion in 
renal cortical slices (Churchill and Ellis, 1993a, Churchill and Ellis, 
1993b, Jin et al., 1998) 
Platelets are known to express P2Y1, P2Y12, and P2X1 receptors 
(Hollopeter et al., 2001). P2Y1 receptors mediate platelet shape change 
and aggregation (Daniel et al., 1998, Hechler et al., 1998). There are 
established therapeutic drugs targetting purinergic antithrombotic 
drugs. The purinergic antithrombotic drugs clopidogrel and ticlopidine 
reduce the risks of recurrent strokes and heart attacks, especially 
when combined with aspirin (Kunapuli et al., 2003, Kam and Nethery, 
2003, Boeynaems et al., 2005). These drugs are antagonists at the 
P2Y12 receptor that mediates platelet aggregation (Gachet, 2001, 
Matsagas et al., 2003). A highly potent and selective antagonist for the 
P2Y1 receptor, MRS2500, has been shown to have antiaggregatory 
activity on human platelets (Cattaneo et al., 2004).  
 
ATP, ADP, UTP, and adenosine are released from platelets and 
endothelial cells by a variety of mechanisms (Kunapuli, 1998, 
Lazarowski et al., 2003). ATP and ADP are released in the heart during 
ischemia from cardiac myocytes, endothelial cells, red blood cells, 
platelets and sympathetic nerves (Gordon, 1986, Burnstock, 1989, 
Ralevic and Burnstock, 1998, Burnstock, 1993). The distribution of 
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P2Y1 receptors on the vascular endothelium indicates a role in the 
regulation of vascular tone, Figure 1. The administration of an 
intravenous injection of MRS2179 (a selective P2Y1 antagonist) was 
reported to result in prolonged bleeding time and inhibition of rat 
platelet aggregation in response to ADP (Baurand et al., 2001). In 
addition, mice treated with MRS2179 and P2Y1-deficient mice both 
showed a significant decrease in arterial thrombosis (Lenain et al., 
2003). Olivecrona et al. (2004) showed that in vivo adminstration of 
MRS2179 in pigs caused a selective inhibition of the P2Y1 receptor and 
of the 2-MeSADP mediated coronary flow increase. They showed that 
MRS2179 significantly reduced the increase in coronary flow caused 
by 2-MeSADP or reactive hyperemia in coronary arteries with no 
significant differences in blood pressure (Olivecrona et al., 2004).  
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Figure 1.1 Purinergic signaling controlling vascular tone. 
 
 
Figure 1.1 Purinergic signalling controlling vascular tone. A diagram illustrating 
the main receptor subtypes for purine and pyrimidines in blood vessels. 
Perivascular nerves release ATP as a cotransmitter: ATP is released with NA and 
neuropeptide Y (NPY) from sympathetic nerves to act on smooth muscle P2X1 
receptors resulting in vasoconstriction. P1(A1)-purine receptors on nerve 
terminals of sympathetic nerves mediate adenosine (arising from enzymatic 
breakdown of ATP) modulation of neurotransmitter release. Endothelial cells 
release ATP and UTP during shear stress and hypoxia to act on P2Y1, P2Y2, and 
P2Y4 purine receptors, leading to the production of NO and EDHF and 
subsequent vasodilatation. ATP, following its release from aggregating platelets, 
also acts on these endothelial receptors. Platelets possess P2Y1 and P2Y12 ADP-
selective purine receptors as well as P2X1 receptors.  For clarity, adenosine 
receptors on platelets and the smooth muscle have been omitted. 
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1.4 Acyl CoA derivatives as endogenous modulators 
 
Fatty acids and related lipids are engaged in cellular metabolism as 
acyl-CoAs. CoA and its acyl derivatives are essential cofactors in all 
living organisms (Leonardi et al., 2005).  Long-chain acyl-CoA esters 
can act as both substrates and intermediates in metabolism and as 
regulators of various intracellular functions. The structure of CoA, and 
its similarity to ADP, is shown in Figure 1.2. In the case of acetyl-CoA 
(AcCoA) (Figure 1.2b), palmitoyl-CoA (PaCoA) (Figure 1.2c) and oleoyl-
CoA (OlCoA) (Figure 1.2d) cleavage of the thioester bond of the CoA 
group yields acetic acid (2:0) (number of carbons/number of double 
bonds), palmitic acid (16:0) and oleic acid (18:1), respectively. Palmitic 
acid is the starting substrate for the synthesis of longer chain fatty 
acids and unsaturated fatty acids into triglycerides, phospholipids and 
cholesterol esters. 
 
Long chain acyl-CoAs are synthesized on the cytosolic face of many 
intracellular membranes resulting in a cytosolic pool where they are 
involved in various processes in the cell. Furthermore, fatty acid 
transport proteins (FATPs) have intrinsic acyl-CoA synthetase activity 
(Uchida et al., 1996, Steinberg et al., 1999a, Steinberg et al., 1999b, 
Coe et al., 1999). Acyl-CoA levels vary significantly in different 
metabolic condition such as diabetes, fasting, fat/glucose feeding and  
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digestion of hypolipidaemic drugs; it was suggested that 20-40% of the 
total fatty acyl pool is cystolic (Oram et al., 1975). The total cellular 
concentration of long chain acyl CoA esters was shown to be in the 
range of 5-160 µmol/L, and acyl CoA binding proteins (ACBPs) and 
fatty acid binding proteins (FABPs) keep the levels of free acyl CoA 
derivatives in a range of 0.1-200 nM intracellularly (Knudsen et al., 
2000).  
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Figure 1.2 Coenzyme A and its derivatives. In blue is the 
fraction of the Coenzyme A structure that is similar to adenosine 
diphosphate (ADP). 
 
 
 
 
 
 
 a. Coenzyme A b. Acetyl CoA c. Palmitoyl CoA d. Oleoyl CoA 
R1= H Acetate Palmitate Oleate 
Molecular 
Weight 
[g/mol] 
767.53 832.56 1005.94 1031.98 
Molecular 
Formula 
C21H36N7O16P3S C23H38N7NaO17P3S C37H66N7O17P3S C39H68N7O17P3S 
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Acyl-CoA is the ligand of acyl-CoA binding protein (ACBPs) that bind 
C14-C22 acyl-CoA esters with high affinity and specificity (Mogensen 
et al., 1987, Kragelund et al., 1999). ABPs were shown to mediate the 
intermembrane transport of acyl-CoAs (Rasmussen et al., 1994). 
ACBPs bind acyl-CoA with 3-4 times higher affinity than that of fatty 
acid binding proteins (FABPs) (Faergeman and Knudsen, 1997, 
Schroeder et al., 2008). Knockdown of ACBP in different cell lines 
caused disturbances in particular cellular functions such as growth 
arrest, impairment in adipocyte differentiation and lethality (Neess et 
al., 2011). In addition, overexpression of ACBP resulted in 
accumulation of triacylglycerol and some other lipid classes in the 
liver of transgenic mice (Neess et al., 2011). Furthermore, ACBPs were 
shown to affect the pool size of acyl-CoA (Schroeder et al., 2008). In 
malignant oesophageal tissue, ACBP genes were shown to be localised 
to endothelial cells in arteries within the connective tissue, while they 
were absent from these cells in the normal oesophageal submucosa 
(McCabe and Innis, 2005).  
 
Palmitoyl CoA hydrolase is an enzyme which utilizes acyl-CoAs as 
substrates and may affect the intracellular concentration of these 
compounds. The enzyme catalyzes the hydrolysis of acyl-CoAs from 6-
18 carbons. In the brain, long-chain acyl-CoA hydrolyzing activity of 
acylCoA hydrolase is much higher than that in any other organ in the 
body (Kurooka et al., 1972, Katoh et al., 1987, Kuramochi et al., 
2002). The catalytic and molecular properties of the long-chain acyl-
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CoA hydrolase present in rat and human brain was clarified (Broustas 
and Hajra, 1995, Broustas et al., 1996, Yamada et al., 1999b). In 
addition, the genomic organization of the human brain acyl-CoA 
hydrolase has also been described (Yamada et al., 1999a). It was 
found that the long-chain acyl-CoA hydrolase present in the brain is 
well-conserved in man and the rat (Yamada et al., 1999a). Although 
the potency of acyl-CoA hydrolases in the modulation of intracellular 
concentrations of acyl-CoAs may provide a regulatory mechanism for 
various cellular functions, the significance for any physiological 
function of brain acyl-CoA hydrolase is still unclear (Yamada, 2005). 
 
Long chain acyl-CoA esters were reported to have high affinity for 
membrane phospholipid bilayers (Powell et al., 1985). Acyl-CoAs were 
shown to associate with cell membranes by insertion of the fatty acyl 
chain into the bilayer core (Boylan and Hamilton, 1992, Peitzsch and 
McLaughlin, 1993). In this regard, PaCoA may be classified as other 
membrane associating surfactants such as lysolipids (Requero et al., 
1995b). The equilibrium partitioning of PaCoA into membranes is 
described by the partition constant Kp which is for PaCoA in the order 
of 1x105 M-1 (Peitzsch and McLaughlin, 1993, Requero et al., 1995a). 
The membrane partitioning of acyl-CoAs has previously been studied 
and OlCoA was shown to have no transbilayer movement in egg 
phosphatidylcholine vesicles (Boylan and Hamilton, 1992). Banhegyi 
et al. showed that PaCoA permeabilized rat liver microsomal vesicles 
(Banhegyi et al., 1996), however, other studies found no solubilization 
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or leakage of egg phosphatidylcholine vesicles by PaCoA (Requero et 
al., 1995b). 
It was found that the oleoyl chain (18 carbons) effectively anchors the 
large CoA molecule to the phospholipid bilayer, while the octanoyl 
chain (8 carbon) results in only weak and transient binding of the CoA 
so it was suggested that the length of the acyl chain can control the 
affinity of the acyl-CoA compounds for membranes, and also their 
residence time in these membranes (Boylan and Hamilton, 1991).  
 
There are no reports describing the presence of acyl-CoA 
extracellularly, although it has been shown that PaCoA synthetase is 
present on the external surface of rat isolated hepatocytes (de Groote 
et al., 1996). However, in certain pathophysiological conditions such 
as heart ischaemia, endurance training, diabetes and acute ischaemic 
stroke (van Breda et al., 1992, Pelsers et al., 1999, Sambandam and 
Lopaschuk, 2003, Wunderlich et al., 2005), the cellular expression of 
FABPs is increased, leading to an overflow of these proteins into the 
blood such that the presence of these FABPs have been suggested to 
be markers of cellular damage. This raises the possibility that the 
FABP may also release the bound ligand into the serum. It was also 
reported that in certain pathophysiological states, high levels of acyl-
CoA accumulate and can cause irreversible damage to cellular 
membranes such as in heart muscle after ischemia and in liver during 
starvation (Bortz and Lynen, 1963, Whitmer et al., 1978). 
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The significance of studies on the effect of acyl-CoAs in vitro and their 
relevance to the situation in vivo has been questioned in some reports, 
where it was postulated that the effects of these compounds on 
cellular functions are caused by their detergent-like properties, 
resulting in rather nonspecific effects, without acting as direct 
homeostatic modifiers of enzymes (Srere, 1965, Taketa and Pogell, 
1966, Shafrir and Ruderman, 1974). However several other later 
reports have contradicted this and shown that acyl-CoA may play a 
regulatory role in vivo under certain circumstances (as shown below). 
Fatty acyl-CoA derivatives have been reported to be potent modulators 
of a variety of cellular functions, activity of transporters, receptors and 
enzymes (Schmidt, 1989). Acyl-CoA compounds were shown to inhibit 
adenine nucleotide translocation through inhibiting the adenine 
nucleotide translocase activity which was reported in heart and liver 
(McLean et al., 1971, Pande and Blanchaer, 1971, Shug et al., 1971, 
Lerner et al., 1972, Harris et al., 1972, Woldegiorgis et al., 1982). This 
can result in lowering of the energy charge of the cell, which may 
affect both muscle contraction and electrical conduction in heart 
(Shug et al., 1975).  
Furthermore acyl-CoAs modulate the activity of some other enzymes, 
receptors and transporters such as glucokinase (Tippett and Neet, 
1982b, Tippett and Neet, 1982a), carnitine palmitoyltransferase I 
(Agius et al., 1987), glucose-6-phosphatase (Fulceri et al., 1993a) and 
the nuclear thyroid hormone receptor (Li et al., 1990). PaCoA inhibited 
the activity of long chain acylCoA synthetase in a reversible manner 
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(Pande, 1973). Both secreted and cellular proteins of the endoplasmic 
reticulum require acyl-CoA derivatives for their acylation (Olson et al., 
1985, Simonis and Cullen, 1986). This reaction appears to have an 
important role in intracellular membrane trafficking (Pfanner et al., 
1989). Acyl-CoA derivatives were also shown to bind to the orphan 
nuclear hormone receptors hepatocyte nuclear factor-ǂ +1)-ǂ
which may influence expression of HNF-ǂ-controlled genes (Hertz et 
al., 1998).  
 
Deeny et al. (1992) showed that acyl-CoA derivatives have a role also 
in the intracellular handling of Ca2+ (Deeney et al., 1992). They 
showed that long-chain acyl-CoA derivatives have a role in the 
cytosolic balance of free Ca2+ by the activation of ATP-dependent Ca2+ 
accumulation (Deeney et al., 1992). It was also shown that acyl-CoA 
derivatives reduced the GTP-induced Ca2+ release from liver 
microsomes (Comerford and Dawson, 1993). CoA and its fatty acyl 
derivatives were also shown to mobilize Ca2+ and play a role in 
regulating Ca2+ fluxes from the intracellular pool in liver (Fulceri et al., 
1993b).  
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1.4.1 Acyl-CoA in pathophysiological states 
Normally fatty acids are mainly used in well-oxygenated hearts (Neely 
et al., 1972, Neely and Morgan, 1974); during ischemia, the 
myocardium is forced to use anaerobic oxidation to oxidize glucose 
and stores fatty acids as triglycerides (Scheuer and Brachfeld, 1966). 
This suggests that a decrease in fatty acid oxidation after myocardial 
ischemia would lead to an accumulation of long chain acyl-CoA esters 
in heart muscle. Schwartz et al. reported that the failure of myocardial 
cells to oxidise large amounts of fatty acids in ischaemic heart can be 
noticed by the rise in acyl carnitine and acyl-CoA concentration in the 
mitochondria, while in the cytoplasm, the increase in acyl-CoA 
concentration can be caused by free carnitine deficiency in ischaemic 
myocardium (Schwartz et al., 1973).   
Furthermore, in pathological conditions such as type 2 diabetes and 
obesity, high circulating levels of free fatty acids lead to accumulation 
of acyl-CoAs in the cytosol (Golay et al., 1986, Reaven et al., 1988, 
Corkey et al., 2000), indicating that this class of compounds may 
contribute to the pathophysiology of obesity and susceptibility to type 
2 diabetes (Riedel and Light, 2005). Chronic free fatty acids exposure 
results in increased levels of acyl-CoAs within ǃ-cells, adding to the 
decreased insulin output through many proposed mechanisms 
(Corkey et al., 2000) including that acyl-CoAs increase KATP channel 
activity (Larsson et al., 1996, Branstrom et al., 1997, Riedel et al., 
2003).  
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1.4.2 Effects of chain length and degree of 
saturation on acyl-CoA activity 
 
Branstorm et al. reported acyl-CoAs as potent activators of the KATP 
channel in human pancreatic ǃ-cells; they also studied the effect of 
chain length of acyl-CoA and found that that only acyl-CoAs with 12 
carbons or more were active and reported a maximal activation of KATP 
channel by PaCoA (C16:0) and noted that there was no further 
increase following addition of OlCoA (C18:1). They also found that long 
chain acyl-CoA stimulated KATP channel activity in human pancreatic 
ǃ-cells in both the inside-out and whole cell preparations which led 
them to the conclusion that these compounds can have an important 
PRGXODWRU\ UROH RI KXPDQ ǃ-cell electrical activity under both 
physiological and pathophysiological conditions (Branstrom et al., 
2004). 
 
Some other reports studied the effect of side chain length and the 
degree of saturation of acyl-CoAs and found that increased acyl-CoA 
side-chain length and saturation led to increased KATP channel 
activity. They concluded that it is possible that dietary fat composition 
may affect the severity of impaired glucose-stimulated insulin 
secretion via differential activation of ǃ-cell KATP channels (Riedel and 
Light, 2005).  
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Back in 1976, acyl-CoA was reported to inhibit ADP-induced platelet 
aggregation (Lin et al., 1976). A number of CoA derivatives were 
investigated in this study; PaCoA 16:0 and other 14:0, 180, 18:1 and 
18:2 derivatives; all these derivatives were more potent than CoA. 
OlCoA and other acylCoA derivatives were also reported to inhibit ADP 
and thrombin-induced platelets aggregation (Lascu et al., 1988). A 
more recent study has investigated  in more details the effects of CoA 
derivatives of different chain length and saturation in platelets 
(Manolopoulos et al., 2008) and this is discussed in the next section 
on modulation of P2Y1 purine receptors by acyl-CoA. 
 
1.4.3 Modulation of P2Y1 purine receptors by acyl-CoA 
 
The structural similarity between the endogenous P2Y1 receptor ligand 
(ADP) and CoA compounds (Figure 2) made it interesting to investigate 
the effect of these compounds on this receptor. Coddou et al., (2003) 
studied whether CoA and CoA derivatives, endogenously derived from 
fatty acids (CoA, AcCoA and PaCoA) or from metabolism of drugs 
(nafenopin-CoA (NafCoA), ciprofibroyl-CoA (CipCoA)), were antagonists 
at recombinant human P2Y receptors expressed in Xenopus laevis 
oocytes (Coddou et al., 2003). CoA was found to antagonize the ATP-
gated currents evoked via the P2Y1 receptor in a concentration-
dependent manner. They also found that of all the CoA compounds 
investigated, NafCoA was the most potent antagonist. In their study, 
they suggested from the structures of the CoA derivatives a possible 
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interaction of the CoA moiety with the P2Y1 purine binding site. In 
addition, they suggested an additional binding site; a hydrophobic 
pocket close to the ligand-binding domain which may involve 
hydrophobic amino acid residues to interact with the hydrophobic 
acyl-substituent. It was reported that the purine binding site for P2Y1 
receptors has several amino acids on the transmembrane domains 3, 
6, 7 and charged amino acids that are part of the extracellular loops 2 
and 3 (Jiang et al., 1997, Hoffmann et al., 1999). Furthermore Major 
et al. (1999) reported the possibility of a hydrophobic pocket close to 
the the P2Y1 receptor ligand binding site; they  found that increasing 
the size of substituents at the C2 or C8 adenine in ATP ligands 
enhanced the affinity of these ligands towards the P2Y1 receptor 
(Major et al., 1999). 
 
In the Coddou et al. (2003) study, they also concluded that both 
higher hydrophobicity and higher bulkiness (lesser flexibility) are 
important for higher antagonist potency. This explains why the 
addition of only two carbons to CoA, as in AcCoA, does not increase 
the potency much compared to CoA because of the lack of bulkiness. 
This importance of the side chain length and hydrophobicity on the 
potency of acyl-CoAs agrees with some other previous reports which 
looked at the effects of side chain length and the degree of saturation 
of acyl-CoAs and found that increased acyl-CoA side-chain length and 
saturation led to increased potency of acyl-CoA compounds at 
different functions, such as in the activation of KATP channel (Riedel 
and Light, 2005).  
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Coddou et al. also tested the selectivity of acyl-CoA derivatives against 
P2X and P2Y2 receptors and showed that none of the CoA derivatives 
interacted with these receptors. They also investigated the action of 
these compounds against 5-HT2 receptors, since both the P2Y1 and 
the 5-HT2 receptors are coupled to Gq/11 and activate a Ca2+ dependent 
chloride channel, and concluded that these compounds probably 
interact with the P2Y1 protein rather than with the signaling pathway 
(Coddou et al., 2003). This study was done on human recombinant 
P2Y1 receptors. 
 
Other studies examined the effect of a number of CoA derivatives at 
endogenous P2Y1 and P2Y12 receptors on platelets; they studied the 
effect of PaCoA (16:0) in depth and showed that PaCoA is an 
antagonist mainly at P2Y1, but also at P2Y12 receptors (Manolopoulos 
et al., 2008). Furthermore, they studied the effect of chain length and 
saturation and found that compounds with saturated acyl groups 
containing 16-18 carbons were the most effective. It was concluded 
that acyl-CoA compounds may contribute as endogenous modulators 
of platelet function (Manolopoulos et al., 2008). The conclusion of 
Manolopoulos et al. about the effects of chain length on acyl-CoA 
activity also agrees with previous literature (Coddou et al., 2003, 
Riedel and Light, 2005). 
 
The effects of acyl-CoA at endogenous P2Y receptors in blood vessels 
are unknown.  
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There are a number of selective antagonists described for the P2Y1 
receptor, such as MRS2179 (Figure 1.3a), which has an IC50 of 0.3 M 
at P2Y1 receptors (Moro et al., 1998), MRS2279 with an IC50 of 51.6 
nM (Boyer et al., 2002) and MRS2500 (Figure 1.3b) with an IC50 value 
of 0.95 nM (Hechler et al., 2006). Nevertheless, it would still be useful 
to identify new compounds which may possess a greater half life in 
vivo and have a greater selectivity and potency at the P2Y1 receptor. It 
is interesting to note that, like CoA and its derivatives, the P2Y1 
receptor antagonists MRS2179, MRS2279 and MRS2500 have 
structural resemblance to the endogenous P2Y1 receptor agonist ADP. 
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Figure 1.3 Chemical structure of MRS2179 (a) and MRS2500 (b), 
potent and selective antagonists of the P2Y1 receptor. 
 
a                                        b 
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Aims and Objectives 
The aim of present study was to investigate the effect of the 
HQGRJHQRXV ´QXFOHRWLGHµ 3D&R$ RQ 3<1 purine receptor-mediated 
responses in blood vessels of different species, namely the rat thoracic 
aorta (RTA), porcine mesenteric artery (PMA), porcine coronary artery 
(PCA), and in human embryonic kidney (HEK) cells using ADP as 
agonist. The effect of CoA and  acyl-CoA, AcCoA and OlCoA, were also 
tested. In addition, the present study aimed to test the selectivity of 
these compounds at these P2Y1 receptors. Furthermore, it was aimed 
to investigate the effect of another endogenous nucleotide, NAD, on P1 
and P2 receptors in RTA, PMA and PCA. Unlike ATP and ADP, the 
effect of NAD on purine receptors is not well explored. 
 
 
 
  
 
 
 
 
 
 
Chapter Two 
Effects of acyl-CoA on P2Y receptor-mediated 
vasorelaxations in rat thoracic aorta  
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2.1 Introduction 
 
The effect of coenzyme A (CoA) and CoA derivatives were investigated 
and shown to be antagonists at recombinant human P2Y receptors 
expressed in Xenopus laevis oocytes (Coddou et al., 2003). CoA 
derivatives were found to antagonize the ATP-evoked currents 
mediated through the P2Y1, but not the P2Y2, receptor in a 
concentration-dependent manner (Coddou et al., 2003). Coddou et al. 
also found that of all the CoA compounds investigated (CoA, 
nafenopin-CoA, ciprofibroyl-CoA, acetyl CoA (AcCoA) and palmitoyl 
CoA (PaCoA)), nafenopin CoA was the most potent antagonist. This 
experiment was conducted using human recombinant P2Y1 receptors. 
Another study examined the effect of acyl-CoA at endogenous P2Y1 
and P2Y12 receptors on human platelets and concluded that PaCoA 
acted mainly at P2Y1, but also evoked a partial antagonism at P2Y12 
receptors and that it may function as an endogenous modulator of 
platelet function (Manolopoulos et al., 2008). The effects of these 
compounds at endogenous P2Y receptors in blood vessels are 
unknown. 
 
ADP induced relaxations are mediated by P2Y1 receptors on the 
endothelium of the rat thoracic aorta (Bultmann et al., 1998). The 
present study investigated, using the rat thoracic aorta, whether the 
relaxation mediated by ADP through the P2Y1 receptor in this tissue 
can be blocked with CoA and its derivatives, AcCoA and PaCoA. 
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Furthermore, it aimed to test the selectivity of these compounds for 
P2Y1 receptors, given that it has previously been shown that P2Y1, 
P2Y2 and A2 receptors are expressed on the endothelium of the rat 
thoracic aorta (Rose'Meyer and Hope, 1990, Hansmann et al., 1997). 
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2.2 Materials and Methods 
 
2.2.1 Rat thoracic aorta preparation and isometric tension 
recording of ADP and UTP responses 
 
Male Wistar rats (200-250 g), obtained from Charles River (England, 
UK), were used in this study. After stunning, they were killed by 
cervical dislocation. The rat thoracic aorta (RTA) was removed and 
placed in oxygenated Krebs-Henseleit solution (composition mmol/l: 
NaCl 118.4, KCl 4.7, MgSO4 1.25, CaCl2 1.2, NaHCO3 24.9, KH2PO4 
1.2, glucose 11.1) in order to rinse off any blood. RTA were then 
placed on a paraffin plate and covered with fresh Krebs-Henseleit 
solution and fine dissection was carried out to remove any excess 
connective tissue. Vessels were then cut into rings (3-4 mm in length). 
Sections from similar locations on each of the vessels used were taken 
each time for consistency. 
 
The rings were mounted gently (to make sure not to damage the 
endothelium) between two stainless steel wire supports one of which was 
attached by a cotton thread to an isometric force transducer (Abingdon, 
Oxfordshire, UK) which measured the tension in the vessels through its 
connection to a Power Lab bridge amplifier (AD instrument, Abingdon, 
Oxfordshire, UK). The other wire was linked to a glass support.  
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Rings suspended on the wire supports were put in water-jacketed 
organ baths which were maintained at a temperature of 37 °C by a 
circulating water heater. Baths were previously filled with 15 ml 
oxygenated (95% O2 and 5% CO2) Krebs-Henseleit buffer solution. 
Mounted rings were initially tensioned to 1 g and allowed to 
equilibrate for 30 min after which a further 1 g of tension was added 
and the rings left to equilibrate for another 30 min. 
 
After the equilibration period, KCl (60 mM) was added and the 
contraction noted once it reached a plateau (usually 15 min). The 
rings were then washed and left for 20 min to relax, after which, the 
same process was repeated. After contraction to the second exposure 
to KCl, the rings were washed and left for 1 h to relax. Only tissues 
which contracted to KCl to at least 0.4 g were used. The second 
contraction to KCl is the only one that was measured. 
 
After the 1 h relaxation period and in order to investigate the relaxant 
properties of the agonists used, the rings were preconstricted with 
methoxamine (0.3-2.0 µM) (Sigma Chemical Company) to a tension of 
55-75 % of the KCl contraction. Stepwise cumulative addition of 
agonist (ADP, UTP) (Sigma Chemical Company) to the preparations 
was then carried out. Each concentration of agonist was left in contact 
with the tissue for 3-6 min to reach a point where no further  
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relaxation was seen. At this point, the next concentration of agonist 
was added. 
 
For checking whether the responses were endothelium dependent or 
endothelium-independent, denudation was achieved by rubbing the 
lumen gently with forceps, and acetylcholine (100 nM) was used to 
assess success in removing the endothelium. Any vessel with a 
relaxation in response to acetylcholine of less than 10% of the 
methoxamine contraction was considered a denuded vessel.  
 
Time control experiments were performed using the same protocol; 
after contracting vessels with methoxamine they were left for an hour 
to check for any loss of tone. 
 
2.2.2 Effect of CoA and acyl-CoA on responses to ADP and UTP 
 
To investigate the possible antagonistic effects of PaCoA, AcCoA, CoA 
(Sigma Chemical Company) and MRS2179 (Tocris) on responses to ADP 
or UTP, these compounds were added after the 1 h relaxation period 10 
min before methoxamine addition. Relaxation²response curves to ADP 
and UTP were then generated as described previously. Only a single 
antagonist was investigated in any one blood vessel ring. 
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In studying the reversibility of the PaCoA antagonism, rings were 
tensioned, equilibrated, KCl added and preconstricted using the same 
protocol described above. Three rounds of addition of ADP (100 µM)  
were performed. In the first round, in the absence of PaCoA, ADP (100 
µM) was added and the response was recorded, after which rings were 
washed out and left for 1hr. Then PaCoA (10 µM) was added 10 min 
before reconstricting with methoxamine, then ADP (100 µM) was 
added to the organ bath and responses were recorded again. The rings 
were then washed again and left for 1 hr after which they were 
reconstricted with methoxamine again and the response to the same 
concentration of ADP was recorded to check the reversibility of the 
PaCoA antagonism. Control experiments were performed using a 
similar protocol, but in the absence of PaCoA. 
 
In separate experiments to check for any direct effect of PaCoA, 10 µM 
was added after contracting the vessels with methoxamine and left in 
the organ bath for 1 hr. Readings were taken every 6 min to check for 
any change in tone.     
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2.2.3 Materials 
The supplier for all chemicals in this work was British Drug Houses 
(BDH, UK) unless otherwise stated. Drugs were dissolved in distilled 
water.  
 
2.2.4 Statistical analysis 
The data were viewed and recorded using Chart for Windows v4.1. 
Results are expressed as mean ± SEM. Two way ANOVA was used for 
statistical comparisons with Bonferroni post-hoc test. A P value < 0.05 
was taken as statistically significant.  
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2.3 Results 
 
Addition of KCl (60 mM) produced a sustained contractile response of 
RTA. The mean tissue response to KCl addition was 0.88  0.02 g 
(n=39). Methoxamine caused a sustained contraction to 55-80% of the 
KCl response. The mean bath concentration of methoxamine required 
to produce this level of contraction was 1.3  0.11 M (n= 39). 
 
2.3.1 Effect of ADP and UTP in rat thoracic aorta 
 
ADP and UTP (0.1 µM- 1mM) were added to the organ bath 
cumulatively. Both elicited concentration dependent relaxations in 
aortic rings precontracted with methoxamine (Figure 2.1). 
 
Figures 2.1a and 3 show the relaxation of rat aorta to ADP; trying to 
use 2 site curve fitting (Prism) to fit lines to the data was 
unsuccessful. One site curve fitting indicated a complete reversal of 
the methoxamine contraction by ADP with maximal relaxation 
observed typically at concentrations of 300 µM or greater. The 
response to ADP did not reach a maximum, but almost fully reversed 
the methoxamine-induced precontraction so approximate values of 
Rmax (103 ± 4), pEC50 (6.00 ± 0.12) and Hill slope (0.81 ± 0.07) (n=19) 
were calculated. Removing the endothelium caused a significant 
inhibition of the ADP-induced responses (Figure 2.1a). 
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In contrast, the response to UTP was biphasic with a peak relaxation 
at 3 µM; concentrations greater than this caused a reduced relaxation 
of the aortic rings (Figure 2.1b). As noticed from the curve, the slope 
was very steep unlike the case with ADP. Non linear analysis for 
responses up to a concentration of 3 M of UTP resulted in Rmax values 
of 94 ± 5, a pEC50 value of 6.64 ± 0.04 and Hill slope of 2.02 ± 0.20 
(n=8).  
Acetylcholine (100 nM) was used to assess endothelium removal. Any 
relaxation in response to acetylcholine of less than 10% of the 
methoxamine contraction was considered a success. There was a very 
slight relaxation (2 ± 0.4 %, n = 6) in response to acetylcholine in 
denuded vessels compared to the profound relaxation evoked in 
controls (65 ± 0.4 %, n = 10).  
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Figure 2.1. Responses of the rat thoracic aorta evoked by a. adenosine 
diphosphate (ADP), in endothelium-intact and -denuded vessels, and b. 
uridine triphosphate (UTP) in endothelium-intact vessels. Vessels were 
precontracted with methoxamine. Data for ADP and UTP are mean  SEM 
(n=6-19, n= 8, for a and b, respectively). 
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2.3.2 Effect of CoA, acyl-CoA and MRS2179 on relaxations to ADP 
 
In the presence of PaCoA (10 µM), AcCoA (10 µM) and CoA (10 µM), the 
mean bath concentrations of methoxamine required to elicit 55-75% of 
the KCl contraction were unchanged when compared to the control (P> 
0.05, one way ANOVA): 1.42  0.18 M, n= 13; 1.56  0.16 M, n= 12; 
1.39  0.17 M, n= 11, for PaCoA, AcCoA and CoA, respectively. 
 
There was a trend for a rightward by CoA to the 
concentration:relaxation response curve to ADP (Figure 2.2a). 1 M, 3 
M and 10 µM CoA did not cause significant shift in the response to 
ADP (Table 2.1). Higher concentrations of CoA were not used due to 
cost considerations. 
 
AcCoA also caused a rightward shift in the concentration:relaxation 
response curve to ADP (Figure 2.2b). Analysis showed that a 
concentration of 10 µM AcCoA caused a 5-fold shift in the relaxations 
to ADP (Table 2.1). Concentrations of 1 M and 3 M CoA had no 
significant effect on the response to ADP. 
 
For PaCoA, a concentration dependent rightward shift in the 
relaxation response curve to ADP was found (Figure 2.2c, 2.3). Schild 
analysis showed that concentrations of 1, 3, 10 M PaCoA caused 
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shifts of 18-, 55- and 331-fold of the response to ADP, respectively 
(Table 2.1).  
 
Figure 2.2d shows the Schild plot for PaCoA; the calculated slope was 
1.73  0.4 with pA2 value of 6.44 ± 0.12 .A log pKB value of 5.32 ± 0.25 
for AcCoA was calculated (n =5). 
MRS2179 (1 M) caused a 29-fold rightward shift of the ADP response 
(Figure 2.4, Table 2.1), allowing calculation, using the Gaddum 
transformation, of an apparent pKB value of 7.32 ± 0.17 (n= 5). 
 
We tested the reversibility of the PaCoA (10 µM) inhibition of the 
response to ADP (100 µM), which was shown to be reversible (Figure 
2.5). The direct effect of PaCoA was assessed and it was shown that 
PaCoA had no direct effect on the RTA when compared to time 
controls (Figure 2.6). 
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Figure 2.2 Adenosine diphosphate (ADP) -evoked relaxation of the rat 
thoracic aorta in the presence of a. coenzyme A (CoA), b. acetyl CoA (AcCoA) 
and c. palmitoyl CoA (PaCoA). d. shows the Schild plot for these curves. 
Vessels were precontracted with methoxamine. Data are shown as mean  
SEM (n= 5-6, n= 6-7, n= 7, respectively). In figure (a) and (b) the data for 1µM 
CoA and AcCoA were removed for clarity. 
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Table 2.1. Effect of coenzyme A (CoA), acetyl CoA (AcCoA), palmitoyl CoA 
(PaCoA) and MRS2179 on ADP evoked relaxations of the rat thoracic aorta. 
Results are mean   SEM. 
 
Table 1 pEC50 Rmax Hill slope 
ADP (control) (n=5) 6.37 ± 0.06 104 ± 6 0.99 ± 0.15 
ADP+ CoA (1µM ) (n=6) 6.19 ± 0.10 111 ± 4 0.87 ± 0.19 
ADP+ CoA (3µM) (n=6) 6.44 ± 0.11 102 ± 5 1.21 ± 0.20 
ADP+ CoA (10µM ) (n=6) 5.74 ± 0.29 106 ± 7 0.84 ± 0.16 
ADP (control) (n=6) 6.19 ± 0.07 101 ± 4 1.0 ± 0.16 
ADP+ AcCoA (1µM) (n=7) 6.00 ± 0.14 98 ± 6 1.06 ± 0.18 
ADP+ AcCoA (3µM) (n=7) 5.54 ± 0.50 112 ± 6 1.07 ± 0.17 
ADP+ AcCoA (10µM) (n=7) 5.51 ± 0.15* 102 ± 14 0.70 ± 0.11 
ADP (control) (n=7) 6.09 ± 0.20 113 ± 7 0.97 ± 0.30 
ADP+ PaCoA (1µM) (n=7) 4.84 ± 0.36* 128 ± 7 0.64 ± 0.08 
ADP+ PaCoA (3µM) (n=7) 4.35 ± 0.26** 122 ± 7 0.81 ± 0.07 
ADP+ PaCoA (10µM ) (n=7) 3.57 ± 0.31*** 127 ± 16 0.80 ± 0.12 
ADP (control) (n=5) 6.37 ± 0.37 125.1 ± 10 0.71 ± 0.21 
ADP+ MRS2179 (1µM) (n=5) 5.07 ± 0.26* 102.3 ± 9 1.07 ± 0.07 
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Figure 2.3. A representative trace for the response of the rat thoracic 
aorta to adenosine diphosphate (ADP) in the absence and presence of 
palmitoyl coenzyme A (PaCoA). Vessels were precontracted with 
methoxamine.  
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Figure 2.4. The effect of MRS2179 on the relaxation of the rat thoracic aorta 
by adenosine diphosphate (ADP). Vessels were precontracted with 
methoxamine. Data are mean  SEM, (n=5). 
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Figure 2.5. Reversibility of PaCoA-mediated inhibition of ADP-evoked 
relaxation of the rat thoracic aorta.  After a control ADP relaxation and 
washout (round 1), ADP was added in the presence of palmitoyl CoA (PaCoA) 
(round 2) and after the washout of PaCoA (round 3). Control experiments 
were performed in the absence of PaCoA. Vessels were precontracted with 
methoxamine. Data are shown as mean  SEM (n= 8). 
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Figure 2.6. The effect of palmitoyl coenzyme A (PaCoA) in the rat 
thoracic aorta compared to time control. Readings were taken every 6 
minutes. Vessels were precontracted with methoxamine. Results are 
shown as mean  SEM (n= 4-5). 
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2.3.3 Effect of CoA, acyl-CoA and MRS2179 on relaxations to UTP 
 
In order to examine the selectivity of CoA analogues, UTP was 
employed as a vasorelaxant. When analyzing the data, this was done 
up to the concentration of 3 M of UTP (at higher concentrations UTP 
started to elicit contraction). 
 
Statistical analysis using two way ANOVA indicated that neither CoA 
(10 µM) nor AcCoA (10 µM) had a significant effect on the relaxation 
response to UTP (Figure 2.7a, b). 
 
For PaCoA, a concentration-dependent rightward shift in the 
relaxation response curve to UTP was observed (Figure 2.7c). There 
was no significant effect of 3 µM PaCoA, while 10 µM PaCoA caused a 
3-fold shift at concentrations of 0.3 and 1.0 µM of UTP. 
 
MRS2179 (1 µM) caused no significant shift in the UTP relaxation 
response (two way ANOVA, Figure 2.7d). 
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Figure 2.7. The response of the rat thoracic aorta to uridine 
triphosphate (UTP) in the presence of a. coenzyme A (CoA), b. 
acetylCoA (AcCoA), c. palmitoyl CoA (PaCoA) and MRS2179 (n= 6-8, n= 
6-8, n=8-10, n=8-12, respectively). Vessels were precontracted with 
methoxamine. Results are shown as mean  SEM. (**) indicate 
significant shift. 
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2.4 Discussion 
 
In the present study, agonists for P2Y1 and P2Y2 receptors, ADP and 
UTP respectively, were used to examine effects of acyl-CoA derivatives 
on the relaxation of preconstricted RTA. The results indicate that, of 
the three acyl CoA derivatives used in this study (CoA, AcCoA and 
PaCoA), the most potent CoA derivative is PaCoA acting as an 
antagonist with apparent selectivity for the P2Y1 receptor in RTA. 
 
2.4.1 Effect of ADP and UTP in rat thoracic aorta 
 
Concentration-dependent relaxation was produced in the presence of 
ADP or UTP. It was previously shown that UTP produced relaxation 
through P2Y2 receptors on the endothelium of the rat thoracic aorta 
(Dol-Gleizes et al., 1999) and in the rat mesenteric arterial 
bed.(Buvinic et al., 2002) This contrasts with the conclusions of Guns 
et al. 2006 investigating mouse thoracic aorta, where they suggested 
that the P2Y2 receptor had no major role in UTP-evoked relaxation and 
that the vasodilator effect of UTP was probably mediated mainly by a 
P2Y6-like receptor (Guns et al., 2006).  
 
ADP was shown to induce relaxations mediated by P2Y1 receptors on 
the endothelium of the rat thoracic aorta (Dol-Gleizes et al., 1999), rat 
mesenteric bed (Ralevic et al., 1995) and mouse aorta (Guns et al., 
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2005). In the current study, we confirmed that the response to ADP 
was endothelium-dependent, since removing the endothelium evoked 
a significant inhibition of these relaxations. 
 
The relaxations mediated by ADP, as shown in Figure 1a, were shallow 
and obviously different from relaxations mediated by UTP which were 
very steep (Figure 1b). This suggests that these two ligands mediate 
relaxations via different receptors, consistent with evidence that ADP 
acts as an agonist at P2Y1, P2Y12 and P2Y13 receptors and that UTP is 
active at P2Y2, P2Y4 and P2Y6 receptors (von Kugelgen, 2006). 
 
In the present study, the pEC50 value of ADP was found to be 6.00, 
similar to the pEC50 value of 6.2 reported for the rat thoracic aorta 
previously (Dol-Gleizes et al., 1999). It is also similar to that found in 
mouse thoracic aorta (6.22) (Guns et al., 2005).  
 
Responses evoked by UTP were biphasic, which may indicate that 
there are multiple elements for this response. The agonist potency 
(pEC50) of UTP in the current study was 6.64. A pEC50 value of 5.83 
was reported for UTP in the rat thoracic aorta (Dol-Gleizes et al., 
1999); in the mouse thoracic aorta, a pEC50 value of 6.46 was found 
(Guns et al., 2006). The authors suggested that responses were 
mediated through P2Y2 and P2Y6 receptors, respectively.  In the former 
study (Dol-Gleizes et al., 1999), non-selective agonists and antagonists 
were used to define the nature of the receptor, while P2Y2 receptor-
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null mice allowed a more defensible identification in the latter 
investigation (Guns et al., 2006). In the current study the 
pharmacology of the UTP responses was not analysed further. 
Whether UTP is acting through P2Y2 or P2Y6 receptors could be 
confirmed by the use of the P2Y6 receptor-selective antagonists, 
MRS2578 or MRS2567 (Mamedova et al., 2004). 
 
At concentrations higher than 3 µM, UTP-evoked relaxations were 
reversed; this may be due to an action on P2Y2 receptors on the 
smooth muscle (Eltze and Ullrich, 1996). This response of UTP was 
not investigated in the current study and all the analysis of the effects 
of antagonists on the UTP response was performed up to the 
concentration of 3 µM. This response for UTP can be tested by 
removing the endothelium to check the effect on these responses. 
Although AR-C118925XX is an example from the literature of a 
selective P2Y2 receptor antagonist with submicromolar activity 
(Meghani, 2002), there are no commercially available P2Y2 antagonists. 
 
2.4.2 Effect of acyl-CoA on concentration-dependent relaxation 
observed with ADP 
 
Antagonism evoked by PaCoA was found to be reversible, which agrees 
with what was reported in Xenopus laevis oocytes (Coddou et al., 
2003). PaCoA was found to have no direct effect on the RTA, 
suggesting there was no tonic activation of the target receptor or 
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activation by PaCoA of other targets in the absence of ADP. PaCoA was 
more potent than CoA and AcCoA as an antagonist at P2Y1 receptors. 
This agrees with the findings in Xenopus laevis oocytes and human 
platelets (Coddou et al., 2003, Manolopoulos et al., 2008). 10 µM 
PaCoA caused an approximately 330-shift of ADP-evoked relaxations, 
while there was a 4- and 5-fold shift in the presence of 10 µM CoA and 
AcCoA, respectively. This increase in potency appears to be due to the 
increase in hydrophobicity from CoA, AcCoA to PaCoA (Coddou et al., 
2003).  The nucleotide moiety of the CoA compounds exhibits 
structural similarities with ADP, which suggests a ligand binding 
domain focussed on the purine binding site. In addition to this 
binding site, it may be that there is a second binding site, a 
hydrophobic pocket adjacent to the purine binding site to 
accommodate the lipophilic acyl-substituent; this pocket would help 
stabilize the interaction of the antagonist with the receptor (Coddou et 
al., 2003) (Chapter One). This could be tested using site-directed 
mutagenesis where alanine scanning could be performed to identify 
the site of action of PaCoA (as well as CoA and other CoA derivatives). 
 
MRS2179 (1 µM) is a selective competitive antagonist at the P2Y1 
receptor (Boyer et al., 2002, Buvinic et al., 2002). In the presence of 
MRS2179, relaxations to ADP were significantly inhibited. The pKB 
value for MRS2179 obtained (7.32) is similar to the one reported in 
human recombinant P2Y1 receptors expressed in Xenopus laevis 
oocytes where it was reported to be 7.7 (Coddou et al., 2003). The pKB 
value calculated was higher than the one reported for turkey 
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erythrocytes (pKB = 6.46 (Boyer et al., 1996a); 6.99 (Boyer et al., 1998). 
In the rat mesenteric arterial bed, a value of 8.03 for the pKB was 
reported (Buvinic et al., 2002). The differences in affinity are 
presumably due to differences in the species or tissues used.  
Methodological differences may also be influential, since the study in 
turkey erythrocytes assessed adenine nucleotide-promoted inositol 
phospholipid hydrolysis response of turkey erythrocyte membranes; in 
the rat arterial mesenteric bed, changes in perfusion pressure were 
measured; while ATP activated currents were studied in Xenopus 
laevis oocytes. 
 
2.4.3 Effects of acyl-CoA on concentration-dependent relaxations 
to UTP 
 
CoA (10 µM) and AcCoA (10 µM) had no significant effect on the UTP 
relaxations, while PaCoA (10 µM) caused a significant rightward shift 
of these relaxations. This shift was small (3-fold) when compared to 
the 330-fold shift PaCoA caused to the ADP-evoked relaxations via 
P2Y1 receptors. This indicates that these compounds are reasonably 
selective for P2Y1 versus P2Y2 receptors. This is consistent with the 
effect of these compounds at recombinant P2Y1 and P2Y2 receptors in 
Xenopus oocytes (Coddou et al., 2003).  
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MRS2179 had no significant effect on UTP-evoked relaxations, 
consistent with responses to UTP acting through a target other than 
the P2Y1 receptor (Buvinic et al., 2002).  
 
2.4.4 Acyl-CoA as an endogenous modulators 
 
The relevance of in vitro studies of acyl-CoA to the situation in vivo has 
been questioned in some reports because of its detergent-like 
properties, which can result in rather nonspecific effects (Srere, 1965, 
Taketa and Pogell, 1966) (Chapter One). However, several other later 
reports have contradicted this and shown that acyl-CoA may play a 
regulatory role in vivo under certain circumstances since many 
enzymes are inhibited by acyl-CoA below the critical micelle 
concentration at which they have detergent-like properties (Harris et 
al., 1972, Lerner et al., 1972, Tippett and Neet, 1982b, Agius et al., 
1987, Li et al., 1990, Hertz et al., 1998, Boylan and Hamilton, 1992) 
(Chapter One).  
 
This maintenance of low concentrations of acyl-CoA is achieved via the 
fact that long chain acyl-CoA have high affinity for phospholipid 
bilayers; this helps to keep low levels of acyl-CoA (Powell et al., 1985) 
(Chapter One). In addition, acyl-CoA binding proteins (ACBPs) and 
fatty acid binding proteins (FABPs) keep the level of free acyl-CoA low 
(Chapter One). It was found that the length of the acyl chain can 
control the affinity of the acyl-CoA compounds for membranes, and 
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also their residence time in these membranes (Boylan and Hamilton, 
1992) (Chapter One). It is possible that this can explain the higher 
potency of PaCoA as an antagonist at membrane P2Y1 receptors 
compared to AcCoA and CoA. 
 
There is no evidence about whether acyl-CoA is present extracellularly 
under normal physiological conditions although it has been shown 
that PaCoA synthetase is present on the external surface of rat 
isolated hepatocytes (de Groote et al., 1996). However in certain 
pathophysiological conditions such as heart ischaemia the cellular 
expression of FABPs is increased, leading to an overflow of these 
proteins into the blood and may also release the bound ligand into the 
serum (Chapter One). In addition, it was also reported that in certain 
pathophysiological states such as fasting, ischaemia and hypoxia, 
high levels of acyl-CoA accumulate and can cause irreversible damage 
to cellular membranes (Bortz and Lynen, 1963, Whitmer et al., 1978) 
(Chapter One). This indicates that this class of compounds may 
contribute to some pathophysiological conditions (Chapter One). The 
possibility that these compounds may be released during 
pathophysiological conditions was also reported (Glatz et al., 1993, 
Vork et al., 1993a, Vork et al., 1993b). Once released, it is possible 
that acyl-CoA derivatives will act as endogenous modulators on many 
levels such as platelet function and vascular regulation (through P2Y1 
receptors) which may implicate a key role of these compounds. The 
present study considered only the effect of CoA and its derivatives on 
P2Y1-mediated blood vessel relaxation, but the vascular P2Y1 receptors 
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is also involved in regulation of endothelium proliferation and 
migration (Shen and DiCorleto, 2008). 
 
CoA and its acyl CoA derivatives were shown to be antagonists at 
human recombinant P2Y1 receptors expressed in Xenopus laevis 
oocytes. (Coddou et al., 2003). Also the effect of acyl derivatives of CoA 
compounds was examined at endogenous P2Y1 and P2Y12 receptors on 
platelets leading to the conclusion that PaCoA is an antagonist at P2Y1 
and has a partial antagonism at P2Y12 receptors and that it may 
function as an endogenous modulator of platelet function 
(Manolopoulos et al., 2008). The effect of chain length has been 
studied and it was found that increased acyl-CoA side-chain length 
increased the potency of these compounds as antagonists at P2Y1 
receptors (Coddou et al., 2003, Manolopoulos et al., 2008, Chapter 
One). The effect of the degree of saturation of acyl-CoAs chain was also 
studied and it was reported that the higher the degree of sauration the 
higher the potency will be for these compounds (Riedel and Light, 
2005 Manolopoulos et al., 2008, Chapter One). In the present study, 
PaCoA was shown to have higher potency as an antagonist at P2Y1 
receptors compared to the shorter-chain acyl-CoAs used, AcCoA and 
CoA, in RTA. This agrees with the above reports about the effect of 
chain length of these compounds. The present study also supports 
suggestions that these compounds can act as endogenous modulators 
of cell-surface receptors. 
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Looking at previous findings of effects of acyl-CoA derivatives (Chapter 
One), and looking at our findings of the effect of PaCoA in blood 
vessels it is clear that these compounds modulate several cellular 
functions, receptors, enzymes and other cellular processes and should 
be considered for further investigations trying to determine their 
patho/physiological significance. In blood vessels it may be especially 
relevant to consider the role of these compounds in pathophysiological 
conditions such as hypertension and they may prove to be relevant in 
the design of novel compounds that degrade or bind and inactivate 
acyl-CoA compounds.   
 
 
[Type text] 
 
 
 
 
 
 
 
 
Chapter Three 
Effect of palmitoyl CoA on ADP-evoked 
vasorelaxations in porcine isolated coronary 
and mesenteric arteries  
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3.1 Introduction  
In the rat thoracic aorta, using isometric tension recording, we 
examined the effects of CoA, AcCoA and PaCoA at vasorelaxant 
endothelial P2Y1 receptors and showed that these compounds are 
antagonists at P2Y1 receptors with PaCoA being the most potent 
(Chapter 2). It is known that species differences can affect both 
agonist and antagonist potencies. For example PPADS was shown to 
be inactive at smooth muscle P2Y1-like receptors in rabbit mesenteric 
artery (Ziganshin et al., 1994), but it blocked those in the rat 
mesenteric arterial bed (Ralevic and Burnstock, 1996). Also significant 
pharmacological differences concerning the antagonist potencies 
between the human and rat P2X4 receptors were identified (Garcia-
Guzman et al., 1996). Therefore, we wanted to investigate whether 
PaCoA would have a similar antagonistic effect in other different 
species and different vessels, so we moved on from rat to pig tissue 
and used two different vessels, specifically porcine mesenteric artery 
(PMA) and porcine coronary artery (PCA).  
 
ADP mediates endothelium-dependent vasodilatation via activation of 
P2Y1 receptors (Nicholas et al., 1996a, Guns et al., 2005); such as in 
rat and mouse mesenteric arteries (Buvinic et al., 2002, Harrington et 
al., 2007). Little is known about P2Y1 in PMA. Endothelial P2Y1 
receptors have also been shown to mediate responses to ADP in PCA 
(Olivecrona et al., 2004). PCA are also reported to express A1, A2A and 
A2B receptors (Merkel et al., 1992, Abebe et al., 1994, Monopoli et al., 
1994, Balwierczak et al., 1991). In a variety of species, coronary 
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arteries express vasorelaxant P2Y receptors on the smooth muscle 
cells (Keef et al., 1992, Corr and Burnstock, 1994, Simonsen et al., 
1997).  
 
In both tissues (PMA and PCA), we started first by generally 
characterising P2Y1 receptors using ADP as an agonist. Then a 
selective P2Y1 antagonist (MRS2500) was used to confirm or exclude 
any involvement of P2Y1 receptors (Kim et al., 2003). Also, by removing 
the endothelium in both PMA and PCA, it was hoped to identify 
whether the receptor involved was located on the endothelium or 
smooth muscle.  
 
The main aim of the present study was to expand our findings in the 
rat thoracic aorta by showing that PaCoA acts as an antagonist of 
P2Y1-mediated, ADP-evoked relaxations in another species and in 
different vessels, specifically in PMA and PCA. Therefore we aimed to 
characterise the effect of ADP on PMA and PCA and to investigate 
whether PaCoA can block the responses mediated by ADP in these 
tissues.  
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3.2 Materials and Methods 
3.2.1 Porcine mesenteric artery and porcine coronary artery 
preparation and isometric tension recordings of ADP responses 
 
Porcine mesenteries and hearts, obtained from a local abattoir (Woods 
abattoir, Clipstone, Mansfield, Nottinghamshire), were placed in 
oxygenated Krebs-Henseleit solution at 4°C before being transported 
to the laboratory. First order porcine mesenteric arteries (PMA) or the 
interior descending branch of the coronary artery (PCA) were dissected 
out, placed in oxygenated Krebs-Henseleit solution in order to rinse off 
any blood, and NHSWRYHUQLJKWDWÝ&The next day, the vessels were 
placed on a paraffin plate and covered with fresh Krebs-Henseleit 
solution and fine dissection was carried out to remove any excess 
connective tissue. Vessels were then cut into rings (3-4 mm in length). 
Sections from similar locations on each of the vessels were taken each 
time for consistency. 
 
PMA and PCA rings were mounted for isometric tension recording as 
described in Chapter Two. Mounted rings were tensioned to 10 g, left 
to relax for 1 h before KCl (60 mM) was added and the contraction 
recorded once it reached a plateau. The rings were then washed and 
left for 20 min to relax, after which, the same process was repeated. 
After contraction to the second exposure to KCl, the rings were 
washed and left for 1 h to relax. Only tissues which contracted to KCl 
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to at least 4.0 g on the second exposure were used. Only values for the 
second contraction to KCl are reported. 
 
For preconstriction, 8 ǂ ǂ-epoxymethano-PGH2 (a 
thromboxane A2 analogue) was used (30- 763 nM) to achieve a tension 
of 50-75% of the KCl-induced contraction. Stepwise cumulative 
addition of agonist (ADP, 0.1 µM- 1 mM) (Sigma Chemical Company, 
UK) to the preparations was then carried out as described in Chapter 
Two. 
 
Endothelium denudation was achieved by rubbing the lumen gently 
with forceps; any vessel with a relaxation in response to substance P 
(10 nM, Sigma Chemical Company) of less than 10% of the U46619-
evoked contraction was considered a denuded vessel. In control 
vessels, substance P caused a rapid, transient relaxation that was 
absent in denuded vessels. Time control experiments were performed 
with the same protocol; after contracting with U46619, vessels were 
left for an hour to check for any loss of tension. Blood vessel tension 
was measured every 6 minutes.    
 
3.2.2 Effect of PaCoA on responses to ADP  
To investigate the possible antagonistic effects of PaCoA (10 µM, Sigma 
Chemical Company) and MRS2500 (1 µM, a selective P2Y1 receptor 
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antagonist, Tocris-Cookson, UK) on responses to ADP, these 
compounds were added 10 min before U46619 addition. 
 
To check for any direct effect of PaCoA, 10 µM was added after 
contracting the vessels with U46619 and left in the organ bath for an 
hour. Blood vessel tension was then measured every 6 minutes.    
 
3.2.3 Immunohistochemical Staining  
 
Porcine mesenteric and coronary arteries were dissected and cleaned 
from any excess connective tissue and cut into 4-5 mm rings. Blood 
vessel rings were fixed in 4% paraformaldehyde and kept overnight at 
4oC. The rings were then washed in phosphate-buffered saline (PBS) 
(Sigma Chemical Company) and frozen with a few drops of OCT 
mounting solution and 10 µm thick slices were created using a 
microtome and transferred to slides and stored at -80oC. 
Whole-mount segments of porcine coronary and mesenteric arteries 
were stained using the standard indirect immunofluorescence 
technique, where the slides were removed from -80oC freezer and 
allowed to equilibrate at room temperature for 30 min. Triton X (Sigma 
Chemical Company) was used as a permeabilizing agent in PBS + 
0.1% bovine serum albumin (BSA) and left for 20 min. Rings were 
then washed out 3 times using PBS+ 0.1% BSA after which human 
serum (Sigma Chemical Company) was used to block any non-specific 
binding in the samples at room temperature for 30 min. After that 
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human serum was aspirated and slices were washed out 3 times, then 
50 µl primary rabbit antibody anti-P2Y1 was added at (1:50) dilution in 
human serum. Samples were incubated overnight at 4ºC. Then they 
were washed with PBS+0.1 % BSA 3 times. The secondary antibody 
anti rabbit IgG (FITC) (1:50) (Sigma Chemical Company) was diluted in 
PBS+0.1% BSA and added to the tissue slices for P2Y1 receptor 
detection. Then the slides were incubated at 37oC for 30 min, followed 
by washing with PBS+ 0.1% BSA 3 times. The slices were then covered 
with vector shield mounting solution and glass cover slips. Samples 
were visualized using fluorescence microscopy using an objective 
magnification of 40X. A parallel set of controls for each slide was 
performed, in the control slides there was no addition for the primary 
antibody.   
 
3.2.4 Materials 
The supplier for all chemicals in this work was British Drug Houses 
(BDH, UK) unless otherwise stated. Antibodies were obtained from 
Calbiochem/Merck Biosciences (Nottingham, UK, anti-A2A Ab) and 
SIGMA (UK, anti-P2Y1 Ab). 
 
3.2.5 Statistical analysis 
Results are expressed as mean ± SEM. Two way ANOVA was used for 
statistical comparisons with Bonferroni post-hoc test. A P value < 0.05 
was taken as statistically significant.  
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3.3 Results 
 
Addition of KCl (60 mM) produced a sustained contractile response of 
PMA and PCA segments; the mean tissue response to KCl addition 
was 8.9  0.32 g (n=25) and 10.2  0.62 g (n=30), respectively. 
 
3.3.1 Effect of ADP in porcine precontracted mesenteric (PMA) 
and coronary arteries (PCA) 
ADP (0.1 µM-1 mM) elicited a concentration dependent relaxation of 
PMA (Figure 1a); maximal relaxation by ADP was observed at a 
concentration of 100 µM. Concentrations of ADP greater than this 
caused a reduced relaxation of the PMA rings (Figures 3.1a, 3.2). Non 
linear analysis of these responses resulted in an estimates of Rmax of 
54 ± 8 %, with a pEC50 value of 6.91 ± 0.19 and Hill slope of 2.0 ± 0.21 
(n=8). Removing the endothelium abolished the ADP induced 
responses (Figure 3.1a). In the absence of endothelium a small 
contractile response was observed at the highest concentrations of 
ADP (Figures 3.1a, 3.2). 
 
ADP (0.1 µM-1 mM) elicited a concentration dependent relaxation of 
PCA (Figure 3.1b); maximal relaxation by ADP was observed at the 
highest concentration (1 mM). Non linear analysis for these responses 
resulted in estimates of Rmax of 94 ± 7, with a pEC50 value of 4.57 ± 
0.25 and Hill slope of 1.30 ± 0.12 (n=10). Removing the endothelium 
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had no significant effect on the ADP induced responses in this tissue 
(Figure 3.1b). 
 
In both PMA and PCA, endothelium removal was assessed using 
substance P (10 nM). Any relaxation in response to substance P of less 
than 10% of the U46619 contraction was considered a success with 
regard to endothelium removal. In denuded PMA and PCA, substance 
P evoked relaxations of 1.43 ± 0.84 % (n = 9) and 3.05 ± 1.26 % (n = 
7), respectively. While in endothelium intact PMA and PCA substance 
P elicited relaxations of 54 ± 3 % (n = 8) and 50 ± 4 % (n = 10), 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
3: Effect of palmitoyl CoA in porcine isolated coronary and mesenteric arteries 
 
76 
 
Figure 3.1. Response evoked by adenosine diphosphate (ADP) in a. 
porcine mesenteric artery, b. Porcine coronary artery. Responses were 
evaluated in endothelium intact vessels (Control, n = 8-10) and in 
those in which the endothelium had been removed (Denuded, n = 7-9). 
Vessels were precontracted with U46619. Results are mean  SEM. 
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3.3.2 Effect of PaCoA on responses to ADP in porcine mesenteric 
arteries (PMA) 
 
PaCoA (10 µM) abolished the relaxation response to ADP in mesenteric 
arteries (Figure 3.2, 3.3a). MRS2500 (10 µM), a selective P2Y1 
antagonist, also abolished the ADP evoked relaxation (Figure 3.3b).  
 
The possible direct effect of PaCoA (10 µM) on vessel tone was 
investigated in the U46619-contracted PMA and was found to be 
without significant effect compared to the time control (Figure 3.5). 
 
U46619 caused a sustained contraction to 56  4 % (n=8) of the KCl 
response. In the absence of antagonists, the concentration of U46619 
required to produce this level of contraction was 36  4 nM (n= 8). In 
the presence of PaCoA (10 µM) and MRS2500 (10 µM) the U46619-
induced contraction was 61 %  2 (n=10) and 65 %  9 (n=4), 
respectively, of the KCl-induced responses. The concentration of 
U46619 required to induce precontraction was unchanged (P > 0.05, 
one way ANOVA). For the direct effect and time control experiments, 
the U46619-induced contraction was 51 %  9 (n= 4) and 56 %  7 (n= 
4), respectively, of the KCl-induced response. The concentration of 
U46619 required to induce precontraction was unchanged compared 
to the control in both time control and direct effect experiments (P > 
0.05, one way ANOVA).  
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 3.3.2.1 Immunohistochemical localization of P2Y1 receptors in 
PMA 
 
Since the ADP-mediated relaxations were blocked by P2Y1 receptor 
antagonists in PMA, the expression of P2Y1 receptors  was investigated 
using immunohistochemistry. P2Y1-like immunoreactivity was 
observed in PMA on the endothelium and smooth muscle (Figure 3.4).  
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Figure 3.2. A representative trace for the response of the porcine 
mesenteric artery to adenosine diphosphate (ADP) in the absence and 
presence of palmitoyl coenzyme A (PaCoA). Vessels were precontracted 
with U46619.  
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Figure 3.3 The response of the porcine mesenteric artery to adenosine 
diphosphate (ADP) in the presence of a. palmitoyl coenzyme A (PaCoA), 
b. MRS2500. Vessels were precontracted with U46619. Results are 
shown as mean  SEM (n=8-10, n=5-4, respectively).  
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Figure 3.4. P2Y1- like immunostaining of the first order porcine 
mesenteric arteries on a. longitudinal sections and c. cross sections of 
the vessels accompanied by a control which had no primary antibody 
to P2Y1 receptors in b. longitudinal section and d. cross section of the 
vessels. Smooth muscle (SM) and endothelial cells (EC) are indicated. 
Scale bar = 100 µm. 
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Figure 3.5. The effect of palmitoyl coenzyme A (PaCoA) on contractile 
responses of the porcine mesenteric artery compared to a time control. 
Readings were taken every 6 minutes. Vessels were precontracted with 
U46619. Results are shown as mean  SEM (n= 4, n=4). In the time 
control group, error bars fall within the symbol. 
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3.3.3 Effect of PaCoA on relaxations to ADP in porcine coronary 
artery segments 
 
Although PaCoA (10 µM) failed to evoke a significant effect on the 
response to ADP (Figure 3.6, 3.7a), there was a trend for a rightward 
shift in the ADP response curve in the presence of PaCoA. MRS2500 
(10 µM), a selective P2Y1 antagonist, also had no significant effect on 
the ADP evoked responses (Figure 3.7b).  
 
 
The direct effect of PaCoA (10 µM) was investigated and it was found 
that PaCoA caused a significant vasorelaxation of the U46619-
contracted PCA compared to the time control (P < 0.05, two way 
ANOVA) (Figure 3.9). The PaCoA direct effect was slow; it took around 
20 min to evoke significant relaxations in response to PaCoA 
compared to the time control. 
 
U46619 in the coronary artery caused a sustained contraction to 59  
4 % (n=8) of the KCl response. The mean bath concentration of 
U46619 required to produce this level of contraction was 13.0  2.5 
nM (n= 8). In the presence of PaCoA (10 µM) and MRS2500 (10 µM), 
the mean bath concentration of U46619 required to elicit 53  4 % 
(n=10) and 56  7 % (n=4), respectively, of the KCl contraction was 
unchanged (P >0.05, one way ANOVA).  
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For the direct effect and time control experiments the U46619-induced 
contraction was 60 %  4 (n= 8) and 50 %  8 (n= 4), respectively, of 
the KCl-induced response. The concentration of U46619 required to 
induce precontraction was unchanged compared to the control in both 
time control and direct effect experiments (P > 0.05, one way ANOVA). 
 
 
  3.3.3.1 Immunohistochemical localization of P2Y1 receptors in 
PCA 
 
The expression of P2Y1 receptors in PCA was investigated using 
immunohistochemistry, and immunoreactivity for P2Y1 receptor was 
observed in PCA on the smooth muscle (Figure 3.8).  
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Figure 3.6. A representative trace for  the response of the porcine 
coronary artery to adenosine diphosphate (ADP) in the absence and 
presence of palmitoyl coenzyme A (PaCoA). Vessels were precontracted 
with U46619.  
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Figure 3.7. The response of the porcine coronary artery to adenosine 
diphosphate (ADP) in the presence of a. palmitoyl coenzyme A (PaCoA), 
b. MRS2500. Arteries were precontracted with U46619. Results are 
shown as mean  SEM (n=10, n=4, respectively). 
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Figure 3.8. P2Y1- like immunostaining of porcine coronary arteries a. 
longitudinal sections and c. cross sections of the vessels accompanied 
by a control which had no primary antibody to P2Y1 receptors in b. 
longitudinal section and d. cross section of the vessels. Smooth 
muscle (SM) and endothelial cells (EC) are indicated. Scale bar = 100 
µm. 
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Figure 3.9. The effect of palmitoyl coenzyme A (PaCoA) in the porcine 
coronary artery compared to time control, readings were taken every 6 
minutes. Vessels were precontracted with U46619. Results are shown 
as mean  SEM (n=8, n=4, for PaCoA and time control data, 
respectively). *** P < 0.001. 
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3.4 Discussion  
PaCoA was used to characterise the effects of ADP on the PMA 
and PCA. We found that PaCoA and the selective P2Y1 receptor 
antagonist MRS2500 abolished the ADP-evoked relaxations 
through the P2Y1 receptor in PMA. In contrast, PaCoA and 
MRS2500 had no significant effect on ADP-evoked responses in 
PCA. 
 
3.4.1 Effect of PaCoA and MRS2500 on ADP evoked 
responses in porcine mesenteric arteries 
In the current study, ADP was observed to cause an 
endothelium-dependent vasorelaxation at concentrations up to 
100 µM, after which there was a reduced vasorelaxation in PMA. 
A pEC50 value of 6.9 was calculated for ADP in the PMA, which is 
similar to the value calculated for ADP activation of P2Y1 
receptors (6.8) in the rat mesenteric arterial bed (Buvinic et al., 
2002). The involvement of P2Y1 receptors was indicated since 
MRS2500 (1 µM) abolished the ADP evoked relaxations. To 
characterise further these ADP responses, PaCoA (10 µM) was 
used; it abolished the ADP-evoked relaxations in the PMA 
indicating that these relaxations were mediated through P2Y1 
receptors. There was no direct effect of PaCoA on these vessels. 
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This is consistent with our finding in the rat thoracic aorta 
where PaCoA acted as a potent P2Y1 antagonist (Chapter 2).  
 
Relaxations to ADP in the PMA were abolished by removal of the 
endothelium. ADP acts as an agonist at endothelial P2Y1 
receptors producing vasodilatation in several blood vessels 
(Ralevic and Burnstock, 1998), while ATP acts as a partial 
agonist at P2Y1 receptors and as an agonist at P2Y2, P2Y6 and 
P2X receptors (Ralevic and Burnstock, 1998). Buvinic et al. and 
Guns et al. showed that, in rat mesenteric arteries and mouse 
thoracic aortae, respectively, the vasodilator effects of ADP, but 
not ATP, were abolished by the P2Y1 receptor antagonist 
MRS2179. On that basis, they suggested that ADP activates 
endothelial P2Y1 receptors in these blood vessels, while ATP does 
not (Buvinic et al., 2002, Guns et al., 2006). 
 
In our study, the ADP evoked vasorelaxation was endothelium 
dependent, consistent with the literature, showing that as in 
most vessels ADP relaxations were mediated through P2Y1 
receptors on the endothelium. Although not studied here, the 
mechanism of endothelium dependent vasorelaxation to ADP is 
likely to involve nitric oxide and EDHF, as shown for endothelial 
P2Y1 receptors in rat mesenteric arteries (Malmsjo et al., 1999, 
Buvinic et al., 2002). 
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In endothelium-denuded vessels, there was a trend for a modest 
contraction in response to ADP. This may indicate 
contamination with ATP, possibly activating a receptor on the 
smooth muscle which may be P2X1, since it is unlikely for ADP 
to act directly at P2X1 receptors (Mahaut-Smith et al., 2000, Vial 
et al., 2003) (Figure 3.1a). This likely accounts for the reduced 
vasorelaxation observed in endothelial-intact vessels at high 
concentrations of ADP. Contamination by ATP could be 
investigated by using an enzyme such as hexokinase which 
selectively hydrolyzes ATP (for example, (Harper et al., 1998)), 
checking the purity of the ADP (HPLC) or using a selective P2X1 
receptor antagonist such as NF449 (Braun et al., 2001).  
 
Similar responses were noticed by Harrington et al. (2007) who 
showed that, in mouse mesenteric arteries, ADP caused a 
dilatation followed by contraction at concentrations 10 µM and 
above; the dilator effects were endothelium dependent, 
indicating that they were P2Y receptor-mediated while the 
constrictor effects were endothelium independent and mediated 
by P2X1 receptors. They concluded the latter response was 
caused by contamination with ATP (Harrington et al., 2007). 
 
There was still a trend, although not significant, for a 
contraction of the PMA at concentrations of 300 µM ADP or 
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above in the presence of PaCoA, similar to what was seen in the 
control ADP responses, which may also indicate that these 
contractile responses are mediated through a distinct target and 
may be caused by ATP contamination activating (most likely) 
P2X1 receptors (as discussed above). The fact that PaCoA did not 
significantly affect these P2X-like contractile responses is also 
consistent with the fact that PaCoA did not act as an antagonist 
at recombinant P2X1 receptors (Coddou et al., 2003).  
 
In an effort to detect P2Y1-like expressed in PMA, using 
immunohistochemistry, P2Y1-like immunoreactivity was 
observed in PMA. However immunoreactivity was observed on 
both endothelium and smooth muscle. This may indicate a lack 
in functional effects of P2Y1 receptors on smooth muscle as our 
results indicate that the ADP-mediated relaxations were 
endothelium dependent and were blocked by P2Y1 antagonists. 
 
In summary, our study in the PMA showed that ADP evokes 
endothelium-dependent vasorelaxation which was abolished by 
PaCoA and MRS2500 and is mediated through P2Y1 receptor. 
PaCoA had no direct effect on PMA. At higher concentrations, 
ADP evoked vasoconstriction which may be mediated through 
contaminating ATP, although this needs to be confirmed using a 
selective P2X1 receptor antagonist.   
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3.4.2 Effect of PaCoA and MRS2500 on ADP-evoked 
responses in porcine coronary arteries 
We have studied the effect of PaCoA on P2Y1 receptor-mediated 
ADP evoked relaxations in rat thoracic aorta and porcine 
mesenteric artery, where PaCoA inhibited these responses in 
both tissues. In this Chapter, we also studied the effect of PaCoA 
on the ADP evoked responses in the PCA. 
ADP elicited a concentration dependent endothelium 
independent relaxation of the PCA. ADP evokes relaxations 
through endothelial P2Y1 receptors in a variety of species and 
blood vessels. In this study, the potency of ADP (pEC50 4.6) in 
PCA was much lower than that observed in the PMA (pEC50 = 
6.9) and to that in the rat thoracic aorta (pEC50= 6.0); in both 
the PMA and the RTA, the ADP response is clearly mediated via 
an endothelial P2Y1 receptor. The ADP potency in PCA observed 
here is similar to previous findings from this laboratory, where 
ADP potency was found to be 5.3 in the PCA (Rayment et al., 
2007b). The maximum response obtained here (94%) was also 
similar to the maximal response previously observed (89%) 
(Rayment et al., 2007b). The small difference in pEC50 values 
could be due to differences in age or sex of the animals between 
the studies. It was reported that ADP mediates endothelium-
independent relaxation via a novel mechanism involving release 
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of adenosine and activation of A2A receptors independently of 
P2Y1 receptors in the PCA (Rayment et al., 2007b). This 
indicates that the PCA is different from other vessels in that ADP 
does not exert vasorelaxation through endothelial P2Y1 receptors 
as it does in other blood vessels, including the RTA and PMA 
studied here. This may explain the difference in the pEC50 
values we found in PMA, RTA and PCA. 
 
Another possibility, other than that ADP may be triggering the 
release of adenosine which then activates A2A receptor (Rayment 
et al., 2007b), is that ADP may be broken down to adenosine 
which then mediates vasorelaxations through A2A receptors 
known to be expressed on PCA (Merkel et al., 1992). This 
possibility was tested by Rayment et al. (2007b) in the PCA 
using a variety of enzyme inhibitors, after which they concluded 
that there was no role for extracellular hydrolysis of ADP in the 
generation of adenosine. In addition, Rayment et al showed that 
relaxations to the hydrolysis-UHVLVWDQWDQDORJXHRI$'3$'3ǃ6
were insensitive to MRS2179 (a selective P2Y1 receptor 
antagonist) and were blocked by A2A receptor antagonists, 
ZM241385 and SCH58261 (Rayment et al., 2007b). 
 
As part of the characterization of these ADP-evoked relaxations, 
we investigated the effect of PaCoA, which failed to affect these 
responses, indicating that they are not mediated through P2Y1 
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receptors. To confirm this, MRS2500 was used, a better 
established P2Y1 receptor antagonist, was used, which also had 
no significant effect on these relaxations.  
 
In an attempt to detect P2Y1 receptors expressed in PCA, using 
immunohistochemistry, P2Y1-like immunoreactivity was 
observed in PCA. Immunoreactivity was observed on the smooth 
muscle. Rayment et al. reported the expression of P2Y1 receptors 
on the PCA smooth muscles (Rayment et al., 2007b). Since 
activation of smooth muscle P2Y1 receptors is thought to lead to 
the activation of Gq/11 G-proteins which will elevate [Ca++]i, this 
is expected to lead to smooth muscle contraction, unlike 
relaxation seen when this receptor is activated on the 
endothelium (Rayment et al., 2007). Our findings in PCA agree 
with their findings that the ADP- mediated relaxations in PCA 
are not mediated via P2Y1 receptors. This may indicate a lack of 
functional P2Y1 receptors in PCA as our results indicate that the 
ADP-mediated endothelium independent relaxations were not 
affected with P2Y1 antagonists. P2Y1-like receptors were also 
reported to be expressed in human coronary artery smooth 
muscle in cultured cells (Strobaek et al., 1996). 
 
 
Interestingly, PaCoA significantly relaxed the U46619-contracted 
PCA in the absence of adenine nucleotides. The response was 
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slow (20 min), compared to the time needed for ADP to cause 
relaxations (3-5 min), perhaps suggesting a direct action on the 
smooth muscle. Although the mechanism by which PaCoA 
mediated these relaxations was not investigated, acyl CoA 
compounds have been reported to evoke responses in other 
tissues; for example, in the rat hippocampus, fatty acyl-CoAs 
enhance glutamate release (Zhang et al., 2000). Additionally, 
fibrates, which are metabolized either as acyl-CoA derivatives or 
as glucuronide conjugates, were reported to have an effect on 
coagulation by inhibiting hepatic fibrinogen synthesis; an effect 
thought to be mediated by PPARǂ peroxisomal proliferator-
activated receptors) (Kockx et al., 1999). PPAR-evoked 
relaxations have been described in a number of smooth muscle 
preparations (see (O'Sullivan et al., 2009) for a review of 
endocannabinoids acting at PPARs).  The mechanism of this 
direct, tissue-dependent relaxatory effect of PaCoA awaits 
further characterization. It should be noted that combining 
PaCoA and ADP in the PCA, did not result in augmentation of 
the relaxation to ADP (see Figure 3.4a); instead it was slightly 
reduced. 
 
In summary, therefore, ADP evoked an endothelium 
independent relaxation of the PCA, which was not mediated 
through P2Y1 receptors since neither PaCoA nor MRS2500 
significantly affected these responses. PaCoA directly relaxed the 
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precontracted PCA, although the mechanism of this action is yet 
to be identified. 
 
3.4.3 Responses in porcine mesenteric and coronary arteries 
 
The characteristic endothelium-dependent vasorelaxation to 
ADP observed in the PMA through P2Y1 receptors is in contrast 
with the atypical response to ADP in the PCA which was 
endothelium-independent, independent of P2Y1 receptors and 
likely to be through enhancing the release of adenosine which 
then acts through A2A adenosine receptors (Rayment et al., 
2007b). Since two vessels from the same species (pigs) were 
being compared, then these differences cannot be due to species 
differences, but rather due to differences in the vessels 
themselves.  
 
In the majority of literature ADP-evoked relaxations are 
mediated by P2Y1 receptors located on the endothelium; 
activation of endothelial P2Y receptors was reported to lead to 
vasodilatation, while activation of P2Y receptors on the smooth 
muscle evokes vasoconstriction (Boarder and Hourani, 1998, 
Kunapuli and Daniel, 1998, Ralevic and Burnstock, 1998, von 
Kugelgen, 2006). In PCA there are also a number of reports of 
adenine nucleotide-evoked relaxation through smooth muscle 
P2Y receptors, especially in coronary arteries in different 
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species; Keef et al. reported P2Y mediated relaxation in guinea 
pig and rabbit coronary artery on the smooth muscle (Keef et al., 
1992), Saetrum Opgaard and Edvinsson reported relaxatory 
responses in human coronary artery via P2Y receptors on 
smooth muscle (Saetrum Opgaard and Edvinsson, 1997). This 
kind of relaxatory response via smooth muscle P2Y receptors 
was also noticed in rabbit and lamb coronary artery (Corr and 
Burnstock, 1994, Simonsen et al., 1997). Rayment et al. (2007b) 
speculated in their report that the endothelium-independent 
action of ADP to evoke the release of adenosine may be a 
common property in the coronary arteries of these species.  
 
The direct relaxatory effect of PaCoA observed in the PCA is also 
in contrast with its action in the PMA and RTA where it did not 
cause any significant response. Whether this response is 
mediated through PPARs is unclear and in need of further 
characterization. 
 
In this Chapter, ADP responses in two different blood vessels, 
PMA and PCA, were assessed. PaCoA and MRS2500 abolished 
the ADP-evoked P2Y1 receptor-mediated relaxations in PMA with 
no direct effect of PaCoA on these vessels. In the PCA, ADP-
evoked relaxations were not mediated through P2Y1 receptors 
and PaCoA had no significant effect on ADP-evoked responses, 
although it caused a significant relaxation of the precontracted 
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blood vessels. These findings highlight a significant difference 
between these two blood vessels and re-emphasize the special 
features of coronary arteries. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter Four 
Effects of acyl-CoA on P2Y receptor-evoked 
calcium responses in HEK cells 
 
 
 
 
 
 
 
 
 
 
 
4: Effects of acyl-CoA in HEK cells  
 
100 
 
4.1 Introduction  
 
Coddou et al. (2003) studied whether CoA and CoA derivatives were 
antagonists at human recombinant P2Y receptors. CoA, drug-derived 
CoA derivatives and CoA derivatives derived from endogenous fatty 
acids were found to antagonize ATP evoked responses at the P2Y1 
receptor, but not at the P2Y2 receptor. Acyl derivatives of CoA were 
also found to act as antagonists at endogenous P2Y1 and P2Y12 
receptors on human platelets (Manolopoulos et al., 2008). Using 
isometric tension recording, we examined the relevance of these 
findings to the regulation of vascular contractility by studying the 
effects of CoA, AcCoA and PaCoA at vasorelaxant endothelial P2Y1 
receptors in the rat thoracic aorta, and showed that these compounds 
are antagonists at P2Y1 receptors with PaCoA being the most potent 
(Chapter 2). In further isometric tension experiments, we tested the 
effect of PaCoA on the ADP evoked relaxation in porcine mesenteric 
artery where PaCoA abolished these relaxations (Chapter 3). 
 
The effect of acyl derivatives of CoA at endogenous P2Y1 receptors in 
human cell lines is unknown. The main aim of the present study was 
to investigate, using HEK cells, whether the increase in intracellular 
calcium mediated by ADP through the P2Y1 receptor can be blocked 
with coenzyme A and its derivatives; AcCoA and PaCoA. Since the 
design of these experiment allowed us to use smaller amounts of the 
test compounds we examined the effect of another CoA derivative, 
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oleoyl CoA (OlCoA), to examine the effect of a longer chain acyl CoA as 
an antagonist at P2Y1 receptors and compare the effect of the number 
of carbons in the acyl residue in AcCoA (acetic acid C2:0), PaCoA 
(palmitic acid C16:0) and OlCoA (oleic acid 18:1) on their antagonistic 
activity; the numbers in brackets indicate the number of carbons and 
double bonds, respectively. Since human embryonic kidney (HEK) 
cells endogenously express both P2Y1 and P2Y2 receptors (Schachter et 
al., 1997b), we were able to test the selectivity of the observed effects 
of ADP at P2Y1 versus effects mediated by UTP at the P2Y2 receptor. 
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4.2 Methods 
4.2.1 Cell Culture 
HEK cells (passages: 27-35, 18-25) taken from the stocks of the 
School of Biomedical Sciences, University of Nottingham were 
JURZQ LQ (DJOH·V 0LQLPXP (VVHQWLDO 0HGLXP (0(0 6LJPD
Chemical Company) supplemented with 10% fetal calf serum 
(FCS, Sigma Chemical Company) and non-essential amino acids 
(Sigma Chemical Company).   
Cells were grown at a temperature of 37°C in a humidified 95% 
air and 5% CO2 atmosphere. All cell culture was carried out 
XQGHUVWHULOHFRQGLWLRQVLQDFODVVƫƫODPLQDUDLUIORZFDELQHW 
4.2.2 Cell Passage 
 
Cells were maintained in 75 cm2 polystyrene cell culture flasks. When 
confluent, cells were prewashed with 2 ml phosphate buffered saline 
(PBS, Sigma Chemical Company), the PBS was aspirated then 2 ml of 
0.25% trypsin/EDTA (Sigma Chemical Company) was added to the 
cells and incubated for 5 min at 37°C. Eight ml fresh media were then 
added to resuspend the cells, which were transferred to sterile 
universal tubes and centrifuged at 1500 rpm for 5 min. The 
supernatant layer was discarded and the pellet was resuspended with 
5 ml fresh media and the cells transferred to new flasks containing 20 
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ml fresh media at a split ratio of 1:5. Cells were cultured for 48 hours 
until they reached confluency.  
 
4.2.3 Preparation of 96 well cell plates 
 
Black-walled 96 well plates (Costar) were first treated with 100 µl poly-
L lysine (Sigma Chemical Company) for 20 min then washed once with 
PBS. Cells from one confluent flask were used to prepare the plate. 
First the flask was washed with 2 ml of PBS then 2 ml of 
trypsin/EDTA added and incubated for 5 min. Fresh media (8 ml) was 
added and the cell suspension was transferred to a tube and 
centrifuged at a speed of 1500 rpm for 5 min. The supernatant layer 
was discarded and the pellet was suspended in 5 ml fresh media; the 
cells were triturated with a pipette to ensure uniform distribution of 
cells. 1 ml of cell suspension was added to a sterile tube containing 24 
ml of fresh media. The suspension was again triturated many times to 
ensure uniform distribution of cells, using a repeater pipette. 200 µl of 
the cell suspension was transferred to each well. Cell plates were 
cultured for 48 hours to reach confluency. 
 
4.2.4 Measurement of changes in intracellular calcium, [Ca2+]i 
 
Changes in intracellular calcium, [Ca2+]i, were investigated using Fluo-
4-AM (Invitrogen). The culture media was aspirated and replaced with 
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the Fluo-4-AM solution in the presence of EMEM media, 10% FCS and 
2.5 mM probenecid (Sigma Chemical Company); 100 µl was added to 
each well and the plates were incubated at 37°C with this solution for 
45 min.   
 
A loading buffer consisting of 250 mM probenecid in HEPES-buffered 
saline (HBSS) was used to wash out the excess dye after the 45 min 
incubation period; the wells were washed two times with this buffer 
each time using 100 µl. After that 100 µl of loading buffer solution or 
antagonists were added to control or antagonists wells respectively 
and incubated with the cells for 30 min after which intracellular 
calcium responses were recorded using a FlexStatioQ ƫƫ SODWH UHDGHU
(Molecular Devices, USA).  
 
All antagonist and agonist dilutions were made using the loading 
buffer solution. Fluorescence measurements were made at excitation 
wavelengths of 485 and 520 nm and an emission wavelength of 515 
nm on the FlexStation II at 37°C. 20 µl of agonists were added at 15 s. 
All added drugs remained in the well until the end of each experiment.  
 
4.2.5 Data analysis   
 
All data were first exported from FlexStation software to Excel, then 
analysed using both Prism version 5 and Excel. For analysis of levels 
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of [Ca2+]i, the mean of the initial fluorescence ratios was taken as a 
baseline (0-16 sec) and was subtracted from subsequent fluorescence 
ratios (16-40 sec). Data collected were from 6 or more different 
experiments and are presented as mean ± SEM. 
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4.3 Results 
4.3.1 Modulation of P2Y receptor-evoked elevations of [Ca2+]i 
in HEK cells 
ADP- and UTP-mediated elevations of [Ca2+]i  were investigated in 
HEK cells using Fluo-4 AM. ADP, at 10 µM, caused a transient 
response with a peak of 32585 ± 2364 RFU (relative fluorescence 
units) over basal (n=11), which occurred within 25-30 seconds of 
drug administration. UTP, at 300 µM, evoked a smaller elevation 
of [Ca2+]i with a mean of 16228 ± 2324 RFU (n = 10), with a 
latency of 23-30 seconds. The response to UTP was 49 ± 4 % of 
the response to ADP. These responses were used as controls, 
and effects of the other compounds were expressed as a 
percentage of the controls.  
ADP-evoked responses were significantly inhibited in the 
presence of either 10 µM PaCoA (residual response 45 ± 9 % of 
control, n = 11) or 10 µM MRS2500 (residual response 5 ± 1 % of 
control, n = 7), but not in the presence of 1 µM PaCoA (Figure 
4.1a). Responses to ADP were not significantly altered in the 
presence of either 1 or 10 µM CoA, AcCoA or oleoyl CoA. 
Responses to UTP were not significantly altered in the presence 
of either 1 or 10 µM PaCoA, CoA, AcCoA, OlCoA or MRS2500 
(Figure 4.1b). 
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Figure 4.1. The effect of CoA and its analogues and MRS2500 on 
[Ca2+]i responses to a. adenosine diphosphate (ADP), or b. uridine 
triphosphate (UTP) in HEK cells. Results are mean  SEM of the 
percentage of the response to 10 µM ADP (n= 7-11) or 300 µM UTP (n= 
7-10), respectively. 
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4.3.2 Effect of palmitoyl CoA on adenine nucleotide-evoked 
[Ca2+]i elevation in HEK cells 
 
ADP and ATP (0.1-100 µM) evoked concentration-dependent 
calcium responses in HEK cells with pEC50 values of 6.7 ± 0.1 (n 
= 3) and 5.6 ± 0.1 (n = 3), respectively (Tables 4.1 and 4.2).  
 
PaCoA (0.1-10 µM) caused a concentration-dependent rightward 
shift in the calcium release evoked by ADP (Figure 4.2a). pEC50, 
Rmax and Hill slope  values for PaCoA are shown in Table 4.1. 
Schild analysis of the effects of PaCoA allowed calculation of an 
apparent pA2 value of 7.2 ± 0.2 using ADP as the agonist, with a 
slope of 1.4 ± 0.2 (n = 3, Figure 4.3a).                
 
PaCoA (0.1-10 µM) also produced a concentration-dependent 
rightward shift in the response curve to ATP (Figure 4.2b). 
pEC50, Rmax and Hill slope values are reported in Table 4.2. 
Schild analysis gave a pA2 value of 7.0 ± 0.3 and a slope of 1.6 ± 
0.2 (n = 3, Figure 4.3b). In order to calculate pA2 values, data for 
ADP and ATP were constrained, where the bottom was fixed at 
zero and the top was fixed to the maximum response evoked in 
the absence of antagonist for each individual experiment. 
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A further set of three experiments was carried out with an 
interval of a year after the previous experiments to increase the 
n numbers; in these PaCoA still significantly affected the 
calcium release evoked by ATP and ADP; the responses were 
abolished at a concentration of 1 µM for both ADP and ATP in 
the presence of 10 µM PaCoA, but PaCoA was less potent when 
compared to the first set of experiments. 
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Table 4.1. The effect of palmitoyl CoA on the calcium response evoked 
by ADP (0.1-100 µM) in HEK cells 
Table  pEC50 value Rmax (RFU) Hill slope 
ADP 6.74 ± 0.11 31062± 3706.95 1.17 ± 0.39 
ADP + 0.1 µM PaCoA   6.27 ± 0.11 31062 0.60 ± 0.15 
ADP + 1 µM PaCoA   5.28 ± 0.10 31062 0.94 ± 0.21 
ADP + 10 µM PaCoA 3.65 ± 0.22 31062 0.81 ± 0.12 
 
Data are mean  SEM, n=3. 
 
Table 4.2.  The effect of palmitoyl CoA on the calcium response 
evoked by ATP (0.1-100 µM) in HEK cells  
Table  pEC50 value Rmax (RFU) Hill slope 
ATP 5.56 ± 0.07 26520 ± 1999 1.55± 0.14 
ATP + 0.1 µM PaCoA 5.36 ± 0.02 26520 1.45± 0.25 
ATP + 1 µM PaCoA   4.40 ± 0.11 26520 0.82± 0.12 
ATP + 10 µM PaCoA   2.58 ± 0.55 26520 0.40± 0.13 
 
Data are mean  SEM, n=3. 
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Figure 4.2. Effect of different concentrations of palmitoyl CoA on the 
calcium response of HEK cells to a. ADP, b. ATP. Results are mean  
SEM, n= 6. 
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Figure 4.3. Schild plots for ADP in the presence of palmitoyl CoA (a) 
and ATP in the presence of palmitoyl CoA (b). Data are mean ± SEM, 
n=3.  
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4.4 Discussion 
In this chapter, ADP and ATP were used to examine effects of 
CoA derivatives on the increase in intracellular calcium 
mediated by P2Y1 receptors in HEK293 human embryonic 
kidney cells. To check the selectivity of these compounds, the 
effect of PaCoA on the UTP- (P2Y2 receptor agonist) mediated 
increase in intracellular calcium was examined. The results 
indicate that, of the CoA analogues examined, PaCoA was the 
only CoA derivative that acts as an antagonist with apparent 
selectivity for the P2Y1 receptor. 
 
4.4.1 Effect of ADP, ATP and UTP on the elevation of [Ca2+]i 
in HEK cells 
Concentration-dependent elevation of [Ca2+]i was produced in 
the presence of ADP, ATP or UTP. It was previously shown that 
ADP, UTP and ATP induced an increase in the [Ca2+]i in HEK 
cells which express P2Y1, P2Y2 and P2Y4 (Fischer et al., 2005, 
Bultmann et al., 1998). 
At the P2Y1 receptor, ADP is a more potent agonist than ATP, 
while ATP and UTP have equal potency as an agonist at P2Y2 
receptors and UTP is a more potent agonist at P2Y4 than ATP 
(Ralevic and Burnstock, 1998). 
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In comparing responses to ADP, ATP and UTP, the potency of 
ADP was >10-fold more than that of ATP (pEC50 of 6.7, 5.6, 
respectively). Maximal responses to UTP were 49% of those to 
ADP. These results are consistent with the fact that uridine 
nucleotides are mostly inactive at P2Y1 and that P2Y1 is more 
sensitive to adenine nucleotide diphosphates than to 
triphosphates (Alexander et al., 2006). 
ADP was slightly more potent in HEK cells (pEC50 of 6.7) 
compared to results obtained previously in the rat thoracic aorta 
(pEC50 = 6.0, Chapter 2) and Dol-Gleizes et al. (1999) (pEC50 of 
6.2) (Dol-Gleizes et al., 1999). The difference in agonist potency 
might be caused by species differences. For example certain 
regions of the P2X7 receptor, residues at positions 127 and 284, 
contribute to differences in agonist potency at rat, human and 
mouse P2X7 receptors (Thompson et al., 2001, Young et al., 
2007). It may also be due to the change from vascular tissue to 
cells or methodological differences, since the rat thoracic aorta 
was studied using isometric tension recording experiments while 
the HEK cell experiments involved measurement of changes in 
[Ca2+]i in monolayers using the FlexStation. 
 
4.4.2 Effect of CoA derivatives and MRS2500 
The present study found that PaCoA is a potent and selective 
antagonist of the native human P2Y1 receptor in HEK cells, 
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while CoA and its derivatives AcCoA and OlCoA failed to have a 
significant antagonistic effect at these receptors. In the rat 
thoracic aorta, CoA or AcCoA caused a significant shift (4-fold, 
5-fold, respectively) in the ADP-evoked relaxations through P2Y1, 
although the shift was relatively small (Chapter 2).  
Coddou et al. (2003) suggested that the increase in potency of 
PaCoA, compared to CoA and AcCoA, may be due to possible 
interaction of the lipophilic acyl-substituent with a hydrophobic 
pocket close to the binding site. In addition they suggested that 
while hydrophobicity is important for the added antagonism, 
maybe bulkiness also plays a critical role. Despite having a 
double bond which reduces flexibility and should increase 
potency according to the Coddou et al paper, OlCoA does not 
follow this trend, as it had no significant effect on the ADP 
responses, although it has higher lipophilicity and bulkiness. 
Our findings agree with the conclusion of Manolopoulos et al. in 
platelets were they observed that CoA analogues containing 
saturated fatty acids provided greater inhibition than those with 
unsaturated fatty acids (Manolopoulos et al., 2008).  
 
The selectivity of the CoA derivatives for the P2Y1 receptors was 
confirmed, as responses to UTP were not significantly altered in 
the presence of PaCoA, CoA, AcCoA and OlCoA. This is 
consistent with the conclusion of Coddou et al (2003) at 
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recombinant P2Y1 and P2Y2 receptors, and with the results in 
rat thoracic aorta (Chapter 2). 
The results of Schild analysis for PaCoA showed apparent pA2 
values of 7.2 and 7.0, with slopes of 1.4 and 1.6 using ADP and 
ATP as agonists, respectively. In comparison with our previous 
investigations of the effects of PaCoA in the rat isolated aorta 
using ADP (pA2 6.44, slope 1.73), there is an increase in affinity, 
with a small reduction in slope, which may result from the 
change from a large tissue mass to a monolayer of cells. Species 
differences may also be responsible for such differences. For 
example  several key residues have been identified to be 
responsible for the species differences in antagonist effects at 
the P2X7 receptor between human and rat (Michel et al., 2008). 
MRS2500 is the most potent and selective P2Y1 receptor 
antagonist currently available (Kim et al., 2003). It displays 100-
fold higher affinity compared with MRS2179 (Waldo et al., 2002, 
Kim et al., 2003) at human recombinant P2Y1 receptors and 
inhibits platelet aggregation to ADP with an IC50 of 0.95 nM 
(Cattaneo et al., 2004). In our study, although it was not 
possible to calculate a pKB value for MRS2500 as only a single 
ADP concentration was used, MRS2500 (10 µM) effectively 
blocked the ADP responses (residual response 5%). Responses to 
UTP were not significantly altered in the presence of MRS2500. 
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These results show that PaCoA is a reasonably potent antagonist 
at human native P2Y1 receptors in HEK cells. This raises the 
possibility of an endogenous selective regulation of purinergic 
signalling involving inhibition of P2Y1 receptors via CoA 
compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Chapter Five 
Effects of NAD on purine receptors-mediated 
responses in rat thoracic aorta and porcine 
isolated coronary and mesenteric arteries  
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5.1 Introduction 
 
Nicotinamide adenine dinucleotide (NAD) (Figure 5.1) is released in a 
variety of smooth muscle tissues during stimulation of nerves 
including those in canine mesenteric artery and human urinary 
bladder (Smyth et al., 2004, Breen et al., 2006). Transporters for NAD 
have been identified that mediate both intercellular and intracellular 
transport of NAD through membranes.(De Flora et al., 2004). NAD has 
been identified as an agonist for P2Y1 receptors in HEK cells 
(Mutafova-Yambolieva et al., 2007), P2Y11 receptors in human 
granulocytes (Moreschi et al., 2006), P2X receptors in human 
monocytes (Grahnert et al., 2009) and can also activate P1 adenosine 
receptors (Burnstock and Hoyle, 1985, Hoyle, 1990). In this chapter, 
responses to NAD in RTA, PMA and PCA were investigated using 
selective P1 and P2 receptor antagonists. In the previous chapters 
PaCoA was shown to act as an antagonist at P2Y1 receptors in rat 
thoracic aorta (RTA) (Chapter Two) (Alexander et al., 2008), porcine 
mesenteric artery (PMA) (Chapter Three) (Alefishat et al., 2010) and in 
HEK cells (Chapter Four) (Alefishat et al., 2009). Hence, we also used 
PaCoA in this Chapter to characterise the responses to NAD in 
different blood vessels, specifically to investigate the possible 
involvement of P2Y1 receptors. 
 
It has previously been shown that vasorelaxant P2Y1, P2Y2 and A2 
receptors are expressed on the endothelium of the RTA (Hansmann et 
al., 1997, Rose'Meyer and Hope, 1990). P2Y1 receptors have also been 
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shown to evoke vasorelaxant responses in PCA (Olivecrona et al., 
2004). PCA are also known to express A1, A2A and A2B receptors 
(Balwierczak et al., 1991, Merkel et al., 1992, Monopoli et al., 1994, 
Abebe et al., 1994). Little is known about purine receptor expression 
in the PMA. However, in Chapter Three, it was observed that ADP 
mediates responses through P2Y1 receptors in the PMA.  
 
The main aim of the present study was to investigate the effects 
of NAD in isolated RTA, PMA and PCA and characterise the 
purine receptors involved in these responses. In addition, the 
effect of PaCoA on these NAD-mediated responses was studied.  
 
Figure 5.1 Chemical structure of nicotinamide adenine dinucleotide. 
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5.2 Materials and Methods 
 
Porcine mesenteries and hearts, obtained from a local abattoir (Woods 
abattoir, Clipstone, Mansfield, Nottinghamshire) and male Wistar rats 
(200-250 g), obtained from Charles River (England, UK) were used in 
this study. PMA, PCA and RTA were dissected out, rings from PMA, 
PCA and RTA were mounted, tensioned, equilibrated, exposed to KCl 
and preconstricted (using methoxamine for RTA and U46619 for PMA 
and PCA) for isometric tension recording as described in Chapters Two 
and Three. Stepwise cumulative addition of agonist (NAD, 0.1 µM- 1 
mM) (Sigma Chemical Company, UK) to the preparations was then 
carried out as described with ADP in Chapters Two and Three. 
 
Endothelium denudation (by gentle rubbing) and time control 
experiments were performed using the same protocol described in 
Chapters Two and Three.  
 
5.2.1 Effect of PaCoA on responses to NAD  
To investigate the possible antagonistic effects of PaCoA (10 µM, Sigma 
Chemical Company), CGS15943 (an adenosine receptor antagonist) (10 
µM) (SIGMA), SCH58261 (a selective A2A receptor antagonist) (100 nM) 
(a gift from Schering Plough, Milan, Italy), suramin (a P2 receptor 
antagonist) (100µM) (Sigma Chemical Company, UK) DQGǂǃmeATP (a 
P2X receptor agonist and desensitizing agent) (10 µM) (SIGMA) on 
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responses to NAD, these compounds were added 10 min before U46619 
or methoxamine addition. 
 
5.2.2 Immunohistochemical Staining  
 
Porcine coronary arteries were stained using the standard indirect 
immunofluorescence technique as described in Chapter three, 50 µl 
primary rabbit antibody A2A was added at (1:50) dilution in human 
serum was added to the slides. Samples were incubated overnight at 
4ºC. Then they were washed with PBS+0.1 % BSA 3 times. The 
secondary antibody anti mouse IgG (TRITC) (1:50) (Sigma Chemical 
Company) was diluted in PBS+ 0.1% BSA and added to the slides 
where we aimed for A2A receptor detection. Then the slides were 
incubated at 37oC for 30 min this was followed by washing with PBS+ 
0.1% BSA 3 times. The slices were then covered with vector shield 
mounting solution and glass cover slips. Samples were visualized 
using fluorescence microscopy using an objective magnification of 
40X. A parallel set of controls for each slide was performed, in the 
control slides there was no addition for primary antibody.   
 
 
5.2.3 Materials 
The supplier for all chemicals in this work was British Drug Houses 
(BDH, UK) unless otherwise stated. All drugs were dissolved in water 
except for CGS15943 and SCH58261 were dissolved in DMSO. 
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Antibodies were obtained from Calbiochem/Merck Biosciences 
(Nottingham, UK, anti-A2A Ab).  
 
5.2.4 Statistical analysis 
Results are expressed as mean ± SEM. Two way ANOVA was used for 
statistical comparisons with Bonferroni post-hoc test. A P value < 0.05 
was taken as statistically significant.  
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5.3 Results 
 
Addition of KCl (60 mM) produced a sustained contractile response of 
segments of RTA, PMA and PCA. The mean tissue response to KCl 
addition in RTA, PMA and PCA was 0.91  0.08 g (n=35), 9.21  0.43 g 
(n=20), and 9.96  0.20 g (n=32), respectively.  
 
5.3.1 Effect of NAD in precontracted rat thoracic aorta, porcine 
mesenteric artery and porcine coronary arteries 
 
In the RTA, NAD evoked concentration-dependent relaxations (Figure 
5.1a, 5.3). The response to NAD did not reach a maximum response at 
concentrations up to 1 mM, but almost fully reversed the U46619-
induced precontraction allowing the calculation of an approximate 
pEC50 value of 4.24 ± 0.19 (n = 9). Endothelium removal resulted in no 
significant effect on the NAD induced relaxations (two way ANOVA, P> 
0.05) (Figure 5.1a). 
 
In PMA segments precontracted with U46619, NAD evoked 
concentration dependent contractions with a maximal contraction at 
300 µM (Figure 5.1b, 5.5). The highest concentration of NAD used (1 
mM) caused a reduced contraction of the PMA. Non-linear analysis 
allowed computation of an Rmax value of 46 ± 8, pEC50 value of 4.54 ± 
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0.22 and a Hill slope of 1.05 ± 0.12 (n=12). Endothelium removal had 
no significant effect on the NAD-induced responses (Figure 5.1b). 
 
 
 
In PCA segments precontracted with U46619, NAD evoked 
concentration dependent relaxations (Figure 5.1c). The response to 
NAD did not reach a maximum response so Rmax, pEC50 or Hillslope 
could not be calculated. Endothelium removal produced no significant 
effect on the NAD induced relaxations (Figure 5.1c). 
 
In PMA and PCA segments, endothelium removal was assessed using 
substance P (10 nM), while acetylcholine (100 nM) was used to assess 
endothelium removal in the RTA. Any relaxation in response to 
substance P/acetylcholine of less than 10% of the 
U46619/methoxamine contraction was considered a success. In 
denuded PMA and PCA, there was an absence of the transient 
relaxation in response to substance P (6 ± 1 % (n = 6) and 2 ± 1 % (n = 
5), respectively) that was seen in control PMA and PCA segments (60 ± 
1 % (n = 11) and 70 ± 1 % (n = 6), respectively). In RTA there was a 
very slight relaxation (2 ± 0.4 %, n = 7) in response to acetylcholine in 
denuded vessels compared to the profound relaxation evoked in 
controls (65 ± 0.4 %, n = 10). 
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Figure 5.1. The effect of nicotinamide adenine dinucleotide (NAD) in 
segments from: a. rat thoracic aorta (RTA) b. porcine mesenteric artery (PMA), 
c. porcine coronary artery (PCA). Arteries were precontracted with U46619. 
Responses were evaluated in endothelium intact vessels (Control) and in 
those in which the endothelium had been removed (Denuded) in each of the 
RTA, PMA and PCA (n= 7-10, n= 6-11, n= 5-6, respectively). Results are mean 
 SEM. 
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5.3.2 Effect of P1 and P2 receptor antagonists on responses to 
NAD in the rat thoracic aorta 
 
Since NAD is able to act as an agonist at the P2Y1 receptor, PaCoA was 
used to investigate whether NAD activates P2Y1 receptors in PCA. 
PaCoA had no significant effect on the vasorelaxant response to NAD 
(P > 0.05, two way ANOVA) (Figure 2a).  
 
Since NAD is able to act as an adenosine receptor agonist, CGS15943 
(a non-selective adenosine receptor antagonist, 1 µM) was used, which 
significantly inhibited the NAD evoked relaxations (Figure 5.2b). 
SCH58261 (an A2A receptor-selective antagonist, 100 nM) was used, 
which also significantly decreased the NAD evoked relaxations with a 
calculated pKB value of  7.25 ± 0.24 (Figure 5.2c, 5.3). The possible 
involvement of A2B receptors was also investigated using MRS1754 (a 
selective A2B receptor antagonist, 1 µM), which had no significant 
effect on NAD-evoked relaxations (Figure 5.2d). 
 
These experiments in rat thoracic aorta were carried out in 
methoxamine-precontracted tissues. In the absence of antagonists, 
methoxamine caused a sustained contraction to 68  6% (n=13) of the 
KCl response. The bath concentration of methoxamine required to 
produce this level of contraction was 1.4  0.2 µM (n= 13). In the 
presence of PaCoA, SCH58261 and CGS15943, the level of tone was 
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70  6% (n= 6), 74  5% (n = 15) and 59  4% (n= 5) of the KCl 
contraction, respectively. There was no significant difference in the 
percentage of contraction to methoxamine in all used antagonists 
compared to the control (P> 0.05 one way ANOVA). In the presence of 
PaCoA, SCH58261 and CGS15943, the mean bath concentration of 
methoxamine required was unchanged when compared to the control 
(one way ANOVA P>0.05). 
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Figure 5.2. Relaxatory responses in the rat thoracic aorta to nicotinamide 
adenine dinucleotide (NAD) in the presence of a. PaCoA, b. CGS15943, c. 
SCH58261 and d. MRS1754. Vessels were precontracted with methoxamine. 
Results are shown as mean  SEM (n=5-6, n=4-5, n=12-15 and n=4-8, 
respectively). 
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Figure 5.3. A representative trace for the relaxatory responses to 
cumulative addition of increasing concentrations of nicotinamide adenine 
dinucleotide (NAD) in the rat thoracic aorta in the absence and the presence 
of SCH58261. Vessels were precontracted with methoxamine. 
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5.3.3 Effect of P1 and P2 receptor antagonists on responses to 
NAD in porcine mesenteric artery 
 
To test for any involvement of P2 receptors in the NAD-mediated 
contractile response, suramin (a P2 receptor antagonist, 100 µM) was 
used; it had no significant effect except at the highest NAD 
concentration where suramin prevented the reduction in NAD-evoked 
contraction (Figure 5.4a). In contrast, ǂǃ-meATP (a P2X receptor 
desensitizing agonist, 10µM) caused a significant inhibition of the NAD 
evoked responses (Figure 5.4b, 5.5). As ǂ,ǃ-meATP abolished the NAD 
response in some vessels an EC50 value could not be calculated. A 
mean contraction of 45  10 % and 17  7 % (n= 7, n=8, respectively) 
at 300 µM NAD was found in the absence and presence of ǂ,ǃ²meATP, 
respectively. 
 
Since NAD can also act as an agonist at the P2Y1 receptor, the effects 
of PaCoA was investigated. PaCoA DWǍ0KDGQR significant effect 
on the response to NAD (P > 0.05, two way ANOVA) (Figure 5.6a).  
 
Since NAD can also act at P1 receptors, the effects of CGS15943 (a 
non-selective adenosine receptor antagonist, 10 µM) and SCH58261 (a 
selective A2A receptor antagonist, 100 nM) were investigated; neither 
had any significant effect on the response to NAD (Figure 5.6b, c). 
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The above experiments in porcine mesenteric artery were carried out 
in vessels precontracted with U46619. In the absence of antagonists, 
U46619 caused a sustained contraction to 75  4 % (n= 7) of the KCl 
response. The concentration of U46619 required to produce this level 
of contraction was 131  18 nM (n= 7). In the presence of PaCoA, 
SCH58261, suramin and ǂ,ǃ-meATP, U46619 elicited  65  9 % (n= 7), 
63  5 % (n= 4), 50  10% (n= 4) and 58  3% (n= 8) of the KCl 
contraction, respectively, which was not significantly different from the 
control (P>0.05, one way ANOVA). The concentration of U46619 
required to produce these contractions was unchanged (P> 0.05, one 
way ANOVA). In the presence of CGS15943, a higher concentration of 
U46619 (763 ± 259 nM, n = 6) was required to precontract the 
preparations compared to that used in the absence of CGS15943 (531 
± 216 nM, n = 7). There was no significant difference in the level of 
tone elicited in the absence and presence of GCS15943 at 55  6% (n 
= 7) and 49  10% (n = 6) of the KCl contraction, respectively. 
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Figure 5.4. the contractile response of porcine mesenteric artery to 
nicotinamide adenine dinucleotide (NAD) in the presence of a. 
suramin, b. ǂǃ-meATP. The arteries had been precontracted with 
U46619. Results are shown as mean  SEM. (n=4, n= 7-8, 
respectively). 
 
-7 -6 -5 -4 -3 -2
-20
0
20
40
60
Control
,  meATP 10 M
[NAD] log M
Co
n
tr
ac
tio
n
 (%
 
o
f U
46
61
9 
c
o
n
tr
ac
tio
n
)
a
b
-7 -6 -5 -4 -3 -2
-20
0
20
40
60
Control
Suramin 100µM
[NAD] log M
Co
n
tr
ac
tio
n
 (%
 
o
f U
46
61
9 
c
o
n
tr
ac
tio
n
)
 
 
 
 
 
  
5: Effects of NAD in vascular preparations  
 
133 
 
Figure 5.5. A representative trace for the contractile response to 
nicotinamide adenine dinucleotide (NAD) of porcine mesenteric artery 
in the absence and presence of ǂǃ-meATP. The arteries had been 
precontracted with U46619.  
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Figure 5.6. The porcine mesenteric artery contractile response to 
nicotinamide adenine dinucleotide (NAD) in the presence of a. PaCoA, b. 
CGS15943, c. SCH58261 (n=7, n=8, n=4, respectively). The arteries had 
been precontracted with U46619. Results are shown as mean  SEM. 
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5.3.4 Effect of P1 and P2 receptor antagonists on responses to 
NAD in porcine coronary artery 
 
Since NAD can act as an agonist at the P2Y1 receptor, PaCoA was used 
to investigate whether NAD activates P2Y1 receptors in PCA. PaCoA 
had no significant effect on the vasorelaxant response to NAD (P > 
0.05, two way ANOVA) (Figure 5.7a).  
 
To characterise the NAD-evoked relaxations, we used CGS15943 
(adenosine receptor antagonist) which, with the exception of the 
response to the highest concentration of NAD (1 mM), abolished the 
NAD evoked relaxations (Figure 5.7b). In the presence of CGS15943, 
contractions were observed at 10-100 µM of NAD. SCH58261 (selective 
A2A receptor antagonist) (100 nM) abolished the NAD-evoked 
relaxations (Figure 5.7c, 5.8).  
 
Since the NAD-mediated relaxations were blocked by A2A receptor 
antagonists, the expression of A2A receptors in PCA was investigated 
using immunohistochemistry; A2A receptor immunoreactivity was 
observed on the smooth muscle in PMA (Figure 5.9).  
 
The above experiments in porcine coronary artery were carried out in 
U46619-precontracted tissues. In the absence of antagonists U46619 
caused a sustained contraction to 60  6% (n=9) of the KCl response. 
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The bath concentration of U46619 required to produce this level of 
contraction was 145  62 nM (n= 9). In the presence of PaCoA and 
SCH58261 U46619 elicited 65  5% (n=5) and 76  2% (n=6) of the 
KCl contraction, respectively, which was not significantly different 
from the control (one way ANOVA P>0.05). The mean bath 
concentration of U46619 required was unchanged (one way ANOVA 
P>0.05).  
 
In the presence of CGS15943, a higher concentration of U46619 was 
required to precontract the PCA preparations; for these experiments 
175 ± 79 nM (n = 7) of U46619 was needed to achieve 57  7% (n = 7) 
of the KCl contraction in controls, while 773 ± 204 nM (n = 6) of 
U46619 was needed to elicit 24  4% (n = 6) of the KCl contraction in 
the presence of CGS15943. Both the level of contraction to U46619 
and the concentration of U46619 required to achieve that level were 
significantly different from the control (P < 0.05, one way ANOVA). 
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Figure 5.7. The porcine coronary artery relaxation to nicotinamide 
adenine dinucleotide (NAD) in the presence of a. PaCoA, b. CGS15943 
c. SCH58261. Preparations were precontracted with U46619. Results 
are shown as mean  SEM (n=5, n=6, n=6 respectively). 
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Figure 5.8. A representative trace for the porcine coronary artery 
relaxation to nicotinamide adenine dinucleotide (NAD) in the absence and 
presence of SCH58261. Vessels were precontracted with U46619.  
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Figure 5.9. A representative A2A receptor immunostaining  of a 
porcine coronary artery in a. longitudinal sections and c. cross 
sections of the vessels accompanied by control which had no primary 
antibody to A2A receptors in b. longitudinal section and d. cross 
section of the vessels. Smooth muscle (SM) and endothelial cells (EC) 
are indicated. Scale bar = 100 µm. 
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5.4 Discussion 
The effects of NAD on the RTA, PMA and PCA were examined. 
NAD evoked vasorelaxations mediated through smooth muscle 
A2A adenosine receptors in the RTA. In the PMA, NAD caused 
vasoconstrictions, which were mediated through P2X receptors. 
In the PCA, NAD evoked vasorelaxation through A2A receptors on 
the smooth muscle. NAD, therefore evokes different effects 
(relaxation or contraction) in different blood vessels acting via 
different receptors. 
5.4.1 Characterisation of NAD-evoked responses in rat 
thoracic aorta  
In the RTA, NAD caused endothelium independent 
vasorelaxations. PaCoA was used to see the effect it had on the 
NAD-evoked relaxations since NAD can act as an agonist at P2Y1 
receptors (Mutafova-Yambolieva et al., 2007). PaCoA had no 
significant effect on the NAD-evoked relaxations. The failure of 
PaCoA to inhibit the NAD-evoked relaxations in the RTA and the 
fact that these relaxations were endothelium independent 
indicates that P2Y1 receptors do not mediate these 
vasorelaxations. 
 
NAD was also shown to act as an agonist at P1 adenosine 
receptors (Hoyle, 1990, Burnstock and Hoyle, 1985), so P1 
receptor antagonists were used to characterise the NAD-
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mediated relaxations. We used CGS15943 (a non selective 
adenosine receptor antagonist) which significantly reduced the 
NAD evoked relaxations indicating the involvement of adenosine 
receptors. To determine which adenosine receptors mediate 
these responses, SCH58261 (a selective A2A receptor antagonist) 
was used. It significantly reduced the NAD-evoked relaxations in 
the RTA. This indicates that NAD-evoked relaxations in the RTA 
are mediated through A2A adenosine receptors. 
 
The relaxations to NAD were not abolished in the presence of 
SCH58261 which may indicate the involvement of other 
adenosine receptors in addition to A2A adenosine receptors. NAD 
has previously been shown to act as an agonist at P1 receptors, 
without specification of which subtype was involved (Burnstock 
and Hoyle, 1985, Hoyle, 1990). Therefore, an A2B adenosine 
receptor antagonist, MRS1754, was used to check for any effect 
on the NAD-evoked relaxations. MRS1754 had no significant 
effect on the NAD-evoked relaxations which excludes the 
involvement of A2B adenosine receptors.   
 
In the RTA, NAD had an approximate pEC50 value of 4.24. This 
is similar to the pD2 value reported by Burnstock and Hoyle 
(1985) for NAD-evoked relaxations in the guinea-pig taenia coli 
5: Effects of NAD in vascular preparations  
 
142 
 
at P1 receptors (4.18), but is somewhat different from the value 
identified by Mutafova-Yambolieva et al. (2007) in HEK cells at 
P2Y1 receptors (6.1). NAD appears to act, therefore, at P1 
receptors, specifically as an A2A receptor-selective agonist. 
 
5.4.2 Characterisation of NAD evoked responses in porcine 
mesenteric arteries  
 
In the current study in the PMA, NAD caused an endothelium-
independent vasoconstriction up to a concentration of 300 µM 
above which it evoked a reduced contractile response.  NAD has 
been identified as an agonist at P2Y1 (Mutafova-Yambolieva et 
al., 2007), P2Y11 (Moreschi et al., 2006), and various P2X 
receptors (P2X1, P2X4, and P2X7) (Grahnert et al., 2009) and can 
also activate P1 adenosine receptors (Hoyle, 1990, Burnstock 
and Hoyle, 1985).  
 
There are no studies in the literature on the effect of NAD on the 
PMA. In the rat mesenteric arterial bed, Ralevic et al. showed 
that NAD, at concentrations above 50 nM, caused biphasic 
responses with a phase of constriction preceding the 
vasodilatation (Ralevic and Burnstock, 1998). It was suggested 
that it is unlikely that P1-purinoceptors mediate the vasodilator 
actions of NAD in rat mesenteric arterial bed; this was based on 
the conclusion of Blackburn et al. and Buss et al. that adenine 
5: Effects of NAD in vascular preparations  
 
143 
 
dinucleotides are largely resistant to degradation (Blackburn et 
al., 1987, Busse et al., 1988, Ralevic et al., 1995).  
 
In this study, the P2 receptor antagonist suramin was used to 
characterise the responses to NAD. It had no significant effect 
except at the highest NAD concentration, where it prevented the 
reduced NAD-evoked vasoconstriction, implying a suramin-
sensitive P2Y receptor-mediated relaxation solely at 1 mM NAD.  
ǂǃ-meATP (a P2X receptor desensitizing agonist) caused a 
significant attenuation of the NAD-evoked contractions, 
suggesting activation of a suramin-insensitive P2X receptor. The 
responses to NAD were not completely abolished in the presence 
RI WKH 3; GHVHQVLWL]LQJ DJHQW ǂǃ-meATP DW  Ǎ0 ,W ZDV
reported previously that rat large mesenteric arteries have 25 - 
100 fold lower sensitivity to ǂǃ-meATP than smaller arteries 
(Gitterman and Evans, 2000). It was also reported that these rat 
large mesenteric arteries are insensitive to the P2 receptor 
antagonist suramin (Gitterman and Evans, 2000). It is likely, 
therefore, that, as relatively large blood vessels were used (first 
order PMA) in this study, that the NAD-evoked contractions were 
mediated through suramin-insensitive P2X receptors on the 
smooth muscle. Whether these responses are mediated through 
P2X1 receptors could be confirmed using a selective antagonist 
such as NF449 (Rettinger et al., 2005). This agrees with the 
conclusion of Grahnert et al. (2009) who showed that NAD acts 
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as an agonist at P2X receptors in human monocytes (Grahnert 
et al., 2009). 
 
Other potential reasons were investigated for the incomplete 
EORFNDGH HYRNHG E\ ǂǃ-meATP of NAD-evoked contractile 
responses in the PMA. Since NAD can also act at P1 receptors, 
CGS15943 and SCH58261 were used. Neither had a significant 
effect on the response to NAD, confirming that these responses 
were not mediated through adenosine receptors. 
 
The reduction in NAD evoked contraction which occurred at the 
highest concentration of NAD (1 mM) was blocked by suramin 
suggesting that it is mediated through P2 receptors. This needs 
further investigation as to whether a contaminant of the NAD, 
for example, ADP or ATP, may be responsible for this relaxation, 
or whether NAD itself activates suramin-sensitive P2Y receptors.  
Evidence from experiments conducted in the presence of PaCoA 
suggested that NAD fails to act through P2Y1 receptors in this 
tissue.  
 
There are no reported potency estimates for NAD acting through 
P2X receptors in the literature. In this study using PMA 
segments, the pEC50 for NAD was 4.54 at P2X receptors. 
Burnstock and Hoyle (1985) reported a pD2 value for P1-
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mediated NAD evoked relaxations in the guinea-pig taenia coli of 
4.18, while Mutafova-Yambolieva et al. (2007) found a pEC50 
value for NAD-evoked calcium responses through P2Y1 receptors 
in HEK cells of 6.1. The potency differences presumably reflect 
simple differences in the receptors being activated.  
 
5.4.3 Characterisation of NAD-evoked responses in porcine 
coronary arteries  
In the current study, NAD caused an endothelium-independent 
vasorelaxation.  Since NAD can act as an agonist at P2Y1 
receptors, the effects of PaCoA on the NAD evoked responses 
were tested. PaCoA had no significant effect on the NAD-evoked 
relaxations, indicating that P2Y1 receptors do not mediate these 
vasorelaxations. 
 
Since NAD can also act as an agonist at P1 adenosine receptors 
(Hoyle, 1990, Burnstock and Hoyle, 1985), adenosine receptor 
antagonists were employed to characterise the NAD-mediated 
responses in the PCA. CGS15943 inhibited these relaxations 
suggesting the involvement of adenosine receptors, without 
allowing identification of the particular subtype. The selective 
A2A receptor antagonist SCH58261 abolished NAD-evoked 
relaxations in the PCA, indicating that NAD evoked relaxations 
in PCA are mediated through A2A receptors. 
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5.4.4 NAD responses in RTA, PMA and PCA 
Recently NAD has been increasingly reported as  an extracellular 
signalling molecule, in addition to its intracellular role (Ziegler, 
2000). The presence of a membrane-bound extracellular NADase 
implies that NAD may function as a physiological modulator of 
central neurotransmission (Khalmuradov et al., 1983, Snell et 
al., 1984). Degradation of NAD yields two second messengers 
that can induce increase of calcium from intracellular stores; 
cyclic ADP-ribose (cADPR) and nicotinic acid adenine 
dinucleotide phosphate (NAADP) (Berthelier et al., 1998, Guse et 
al., 1997). NAD can be cleaved by ectoenzymes. Nucleotide 
phosphodiesterase/pyrophosphatase I (E-NPP, CD203 family) 
allows the production of AMP, which can be hydrolyzed to 
adenosine by ecto-5Ļ-nucleotidase (CD73). 
 
There are a number of shared properties between NAD and ADP.  
They both have significant roles in energy metabolism, they also 
act as substrates for extracellular enzymes which in turn 
generate a number of metabolites that may have signalling 
functions (Ziegler, 2005). For example, NAD serves as a 
substrate for mono-ADP-ribosyltransferases (ARTs) that catalyze 
the transfer of ADP-ribose from NAD to target proteins (Moss et 
al., 1990). NAD can also be used by CD38 and CD157; both 
have NAD-glycohydrolase and ADP-ribose cyclase activity, 
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resulting in the formation of ADP-ribose (ADPR) and cyclic ADP-
ribose (cADPR) (Berthelier et al., 1998). Transmembrane 
transporters were identified for both NAD and cADPR (Bruzzone 
et al., 2001, Romanello et al., 2002, De Flora et al., 2004). These 
transporters mediate intracellular and intercellular trafficking of 
NAD and cADPR that enhances intracellular [Ca2+]i (De Flora et 
al., 2004). 
 
Unlike ADP there are very few reports about intact NAD 
triggering intracellular events through surface receptors. NAD 
was reported to be released on nerve stimulation in blood 
vessels and urinary bladder in human, mouse and dog, and was 
demonstrated to have characteristics of a neurotransmitter 
(Breen et al., 2006, Mutafova-Yambolieva et al., 2007, Smyth et 
al., 2004). NAD was reported to act as an agonist at P2Y11 
receptor in granulocytes (Moreschi et al., 2006). Mutafova-
Yambolieva et al. reported that NAD acts as an agonist at P2Y1 
receptors (Mutafova-Yambolieva et al., 2007). NAD was also 
reported to facilitate Ca2+ influx, pore formation and cell death 
through acting as a substrate for mono-ADP-ribosyltransferase 2 
(ART2), an enzyme that catalyzes ADP-ribosylation of P2X7 
receptors (Seman et al., 2003). An increase in [Ca2+]i in 
responses to extracellular NAD was reported in several cell types 
through the conversion of NAD into cADPR which in turns 
mobilises intracellular Ca2+ (Sun et al., 1999, Verderio et al., 
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2001, Esguerra and Miller, 2002, Romanello et al., 2002, De 
Flora et al., 2004). In human monocytes, exposure to NAD 
resulted in a rapid increase in [Ca2+]i caused by an influx of 
extracellular Ca2+ independent of intracellular Ca2+ (Gerth et al., 
2004); in this tissue, the possibility of NAD acting through a 
degradation product was ruled out using selective inhibitors of 
CD38 and a stable NAD analogue. Interestingly, in this study 
the increase in [Ca2+]i was inhibited in the presence of ATP 
(Gerth et al., 2004). The possibility of NAD acting through an 
ATP receptor was investigated and led to the finding that NAD 
acts as an agonist at P2X receptors, an action inhibited in the 
presence of ATP which led to the speculation that since NAD and 
ATP have a similar mechanism to increase [Ca2+]i it is possible 
that ATP can control the fate of NAD by making it available to 
other pathways (Grahnert et al., 2009). 
 
In this study, NAD appeared to act through distinct receptors in 
different vascular beds.  In the PMA, NAD appeared to act 
through P2X receptors, which agrees with the findings of 
Grahnert et al. (2009) in human monocytes. Pfister et al. (2001) 
analyzed the NAD degradation products in human monocytes, 
and found that NAD was mainly degraded to ADP-ribose, 
nicotinamide, and minor amounts of AMP, ADP, and cADPR 
(Pfister et al., 2001). Adenosine was not detectable. If produced 
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sufficiently, all of these by-products have signalling functions 
mediated through different receptors. Based on this, Grahnert et 
al. (2009) concluded that NAD in human monocytes engages 
with P2X receptors as none of their by-products except ADP 
have been described to interact with P2X receptors. In the 
current study, it is not possible to confirm whether NAD acts 
directly at P2X receptors in the PMA or through its metabolites, 
mainly ADP. This can be confirmed using enzymes such as 
apyrase, a nucleoside diphosphatase that can catalyse the 
removal of the beta phosphate from ADP but fails to hydrolyze 
NAD (Babu et al., 2002).  
 
In the RTA and PCA, it was observed that NAD evoked 
relaxations via A2A receptors. This may be by acting directly at 
A2A receptors, causing the release of adenosine or being broken 
down into adenosine. Blackburn et al. and Buss et al. suggested 
that adenine dinucleotides are largely resistant to degradation 
(Blackburn et al., 1987, Busse et al., 1988). This contrasts with 
the conclusion of Nikiforov et al. that NAD+ needs to be degraded 
outside the cell to serve as precursors of intracellular NAD 
(Nikiforov et al.). This also contrasts with the finding of Bruns 
(1980) who suggested that NAD needs to be broken down to act 
on adenosine receptors in human fibroblasts (Bruns, 1980). 
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These findings in the RTA and PCA agree with observations of 
Burnstock and Hoyle (1985) who reported that NAD acts in the 
guinea-pig taenia coli through P1 receptors. Using dipyridamole 
(a purine nucleoside uptake inhibitor) and 8-phenyltheophylline 
(a P1 receptor antagonist) they showed that the dominant 
mediator of NAD-induced relaxations is adenosine, and they 
reported two possibilities, which were that NAD either induces 
release of adenosine or is broken down to adenosine. They then 
concluded that NAD acts on P1 receptors probably indirectly, 
following its conversion to adenosine. NAD was reported to evoke 
the release of adenosine in rat vas deferens, guinea-pig taenia 
caecia and bladder (Stone, 1981).  
 
NAD evoked endothelium independent vasorelaxation in the RTA 
and PCA through smooth muscle A2A receptors. Whether these 
responses are caused by NAD activating A2A receptors directly, 
by causing a release of adenosine or by being broken down into 
adenosine is in need of further characterisation. The role of 
adenosine could be confirmed by the use of the enzyme 
adenosine deaminase to degrade adenosine to inosine, a much 
less active metabolite. Furthermore, hydrolysis of NAD could be 
investigated using selective inhibitors of CD38 (an NAD-
glycohydrolase), VXFK DV ǃ-araF-NAD (Muller-Steffner et al., 
1992). Radiolabelled NAD, such as carbonyl-14C NAD, could also 
be used to check the stability of this compound in contact with 
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vascular tissue. The use of HPLC with mass spectroscopy to 
determine extracellular levels of 1$'DQGLW·VPHWDEROLWHVcould 
also be undertaken (Slominska et al., 2006). 
The relaxations evoked by NAD were significantly reduced in the 
presence of SCH58261 in RTA, while SCH58261 abolished these 
NAD-evoked relaxations in PCA which may give an indication 
that in RTA the NAD evoked relaxations may involve other 
receptors that also mediate this relaxatory response. 
In conclusion, there are clear differences in the actions of NAD 
in the PMA compared to the RTA and PCA; in both RTA and 
PCA, NAD acts through P1 receptors, while in PMA it appears to 
act through P2X receptors. The suggestion that NAD may be 
broken down to adenosine to act through P1 receptors may 
indicate higher levels of ectonucleotidases in RTA and PCA.  
[Type text] 
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In this project, effects of acyl-CoA derivatives were examined on 
responses mediated by P2 and P1 receptors in RTA, PMA, PCA 
and HEK cells. Table 1 shows vasorelaxant purine receptors in 
the blood vessels used in the previous chapters, as 
characterised in our studies and as reported in literature. It can 
be seen that in the aorta and mesenteric arteries P2Y1 receptors 
are expressed on the endothelium, but in coronary arteries these 
have only been reported on the endothelium in the pig 
(Olivecrona et al., 2004) but this is controversial (Rayment et al., 
2007, Chapter Three, Five). P2Y2 receptors also appear to be 
expressed on the endothelium of aorta and mesenteric arteries, 
but a recent study in mouse aorta raises the possibility that 
these may be P2Y6 receptors (Guns et al., 2006). Nonetheless, 
the expression of at least two different vasorelaxant P2Y purine 
receptors in all three of the blood vessels allowed us to 
investigate the selectivity of CoA and its derivatives as possible 
P2Y1 antagonists. In aorta, coronary and mesenteric arteries A2A 
and A2B receptors are expressed on both EC and SM (Table 6.1). 
 
The present results indicate that, of all the acyl CoA derivatives 
used in this study (CoA, AcCoA, OlCoA and PaCoA), the most 
potent CoA derivative was PaCoA acting as an antagonist with 
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apparent selectivity for the P2Y1 receptor in RTA, PMA and HEK 
cells. 
Acyl-CoAs are essential intermediates in lipid biosynthesis and 
fatty acid metabolism. The possibility that acyl-CoAs play a 
physiologically significant role as endogenous modulators has 
received increasing attention (Chapters One and Two). Despite 
their non-specific effects which are evoked by their detergent 
properties, normally they are kept at low levels intracellularly by 
ACBPs and FABPs and these relatively low concentrations 
specifically and reversibly affect several transport and enzyme 
systems (Chapters One and Two).  
 
Several studies have described different effects of acyl-CoA on a 
variety of cell functions and suggested that acyl-CoA can play a 
key regulatory role under certain circumstances (Chapter Two).  
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Table 6.1. Vasorelaxant purine receptors in aorta, coronary and 
mesenteric blood vessels in various species. 
Vessels Species Receptors location Rferrences 
Aorta guinea-pig A2B EC,SM Hargreaves et al., 1991, Martin, 
1992, Martin et al., 1993b, 
Gurden et al., 1993, Alexander 
et al., 1994 
    
P2Y1, P2Y2, P2Y6, 
P2Y4 EC Kaiser et al., 2002 
  
rat A2A, A2B EC, SM conti et al 1993, Lewis et al., 
1994, Monopoli et al., 1994, 
Prentice and Hourani, 1996, 
Chapter Five 
  
  P2Y1, P2Y2 EC Bultmann et al., 1998, Dol-
Gleozes et al., 1999 Chapter 
Two 
  mouse 
A2A, A2B EC,SM Ponoth et al., 2009,Talukder et 
al., 2002, Ansari et al., 2006 
    P2Y1, P2Y2, P2Y6 EC 
Beny et al., 2004, Guns et al., 
2006  
Coronary   
   
  pig 
A2A, A2B EC, SM Balwierczak et al., 1991, Abeb et 
al., 1994, Monopoli et al., 1994, 
Rayment et al., 2007, Chapter 
Three, Chapter Five 
    P2Y1  EC Olivercrona et al., 2004 
  lamb P2Y EC, SM simonsen et al., 1997 
  mouse A2A, A2B EC, SM 
Feoktistov et al., 1997, Talukder 
et al., 2002 
  bovine A2A ___  Conti et al 1993 
  
guinea-pig 
isolated heart A2A ___  Erga et al., 2000 
mesenteric   
   
  pig A2A SM Chapter Five 
    P2Y1 EC Chapter Three 
  rat A2A EC, SM Hiley et al., 1995 
    A2B SM Rubino et al., 1995 
    P2Y1, P2Y2, P2Y4 EC Malmsjo et al., 2000 
    P2X SM Ralevic, 2002 
  rabbit A2A EC 
Balwierczak et al., 1991, de Brito 
et al., 2002 
    P1, P2 SM Mathieson and Burnstock, 1985 
  mouse P2X1 EC Harrington et al., 2007 
    P2Y6 EC Koltsova et al., 2009 
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The extracellular existence of acyl-CoAs appears unlikely under 
normal physiological conditions. However, they may be released 
during pathophysiological conditions (Chapter Two). In this 
investigation, PaCoA was shown to act as a potent antagonist 
with apparent selectivity for P2Y1 receptors (Chapters Two, 
Three, Four and Five). However, the mechanism by which PaCoA 
acts remains to be clarified. The simplest interpretation is that 
CoA compounds, because of their structural similarity with ADP, 
compete for the same binding site of the P2Y1 receptor at the 
extracellular surface. The possibility of whether PaCoA can 
inhibit these receptors extracellularly and whether there is a 
possibility that transport proteins may move PaCoA to 
extracellular compartments under certain conditions is yet to be 
investigated. Another possibility is that acyl-CoA derivatives may 
act on the intracellular face of the plasma membrane to regulate 
P2Y1 receptor function. In addition, acyl-CoAs were shown to 
associate with cell membranes by insertion of the fatty acyl 
chain into the bilayer (Powell et al., 1985). So whether the action 
of these compounds is facilitated by the fact that these 
compounds are actually integrated into the right place, in 
membranes, which make them available to interact with P2Y1 
receptors is an interesting possibility to investigate. 
Furthermore, it was suggested that in some cases ACBP donates 
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acyl-CoA directly to the site of action (Faergeman and Knudsen, 
1997). However this ability to donate acyl-CoA does not always 
occur since AcCoA bound to ACBP was unable to inhibit AcCoA 
carboxylase (Rasmussen et al., 1994). So whether bound acyl-
CoAs are still available for binding to some specific enzymes or 
even receptors is in need of further investigation. 
The way by which  these compounds act can be tested using 
isolated lipid rafts since P2Y1 receptors have been shown to 
associate with lipid rafts (Volonte et al., 2007). By incubating 
these isolated lipid rafts with tritiated PaCoA and/or CoA, it 
should be possible to check for co-localization of P2Y1 receptor 
with PaCoA which may help to explain the action of PaCoA as an 
antagonist at P2Y1 receptors.  
 
Another approach would be to make use of cells or cell 
fragments that natively express P2Y1 receptors, such as 
platelets, and heterologously-expressed receptors in cells such 
as 1321N1 cells, an astrocytoma cell line that does not express 
endogenous purine receptors. Injecting these cells with a 
calcium-sensitive dye and PaCoA (or CoA, etc.) simultaneously 
and following any change in Ca2+ signalling in response to 
extracellular ADP addition could be compared with the action of 
external PaCoA application on ADP addition. In whole cell patch 
clamp experiments Shumilina et al. have reported in Chinese 
hamster ovary cells and HEK cells the ability of endogenously 
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produced acyl-CoA to modulate the activity of KATP and Kir 
channels (Shumilina et al., 2006).   
 
The use of mice in which the gene encoding for P2Y1 receptors is 
disrupted should allow confirmation of the target of ADP and 
PaCoA. In addition to the action of PaCoA on vascular cell-
surface P2Y1 receptors, it will be useful to test the response of 
these compounds on mitochondrial P2Y1 receptors (Belous et al., 
2004, Belous et al., 2006).  Given intracellular nucleotide levels, 
it appears likely that these receptors are in a continuously 
activated state.  Using isolated mitochondria, it should be 
possible to test the effects of the endogenous ligands, ADP and 
ATP, as well as PaCoA.  It is conceivable that high intracellular 
levels of PaCoA allow the mitochondria to be protected from 
nucleotide-evoked desensitisation, which is only relieved when 
PaCoA is metabolised.  The phenomenon observed of PaCoA-
mediated inhibition of vascular, cell-surface P2Y1 receptors may 
MXVWEHD¶KDQJRYHU·IURPWKHLQWUDFHOOXODUORFDWLRQDQGIXQFWLRQ
of PaCoA. 
 
In vivo administration of P2Y1 antagonists, MRS2179 and 
MRS2500, has been performed in pigs and mice, respectively, 
which gave further evidence for a role of the P2Y1 receptor in 
post ischemic hyperemia and thrombosis (Olivecrona et al., 
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2004, Hechler et al., 2006). MRS2179 and MRS2500 
significantly reduced the post-ischemic hyperemia and inhibited 
both systemic and localized arterial thrombosis, respectively; 
this supports the concept that targeting the P2Y1 receptor can be 
a reasonable complement or alternative to current clinical 
management of reperfusion injury in the treatment of acute 
myocardial infarction and in antithrombotic therapy (Olivecrona 
et al., 2004, Hechler et al., 2006). PaCoA is an attractive lead for 
assessing these in vivo effects, since it was reported to have 
antiplatelet activity acting mainly at P2Y1 receptors ex vivo and 
to be antagonist at recombinant P2Y1 receptors (Coddou et al., 
2003, Manolopoulos et al., 2008) and, in this study, to be an 
antagonist at endogenous vascular P2Y1 receptors in RTA and 
PMA, as well as at native P2Y1 receptors in HEK cells (Chapters 
Two, Three, Four and Five).  If such actions are reproduced in 
vivo, PaCoA could be used as a lead compound for the 
development of even more selective and potent antagonists and 
possibly radioligands at the P2Y1 receptor.  
 
Although both the mechanism of action and the in vivo effects of 
acyl-CoA derivatives have yet to be clarified, it is an attractive 
field to explore and if these effects can be confirmed in vivo, 
there is a possibility that acyl-CoAs may add to the 
understanding and management of pathophysiological 
conditions such as hypertension, diabetes, thrombosis and 
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many more disorders. Interestingly, the action of PaCoA on 
blood vessels that was found in this study using RTA and PMA, 
where PaCoA was found to block the ADP-mediated relaxations 
at P2Y1 receptors, may indicate a role in the severity of 
hypertension. If this can be demonstrated in vivo, it may suggest 
that CoA compounds could be used as leads in the design of 
molecules that may have the ability to prevent the interaction of 
endogenous PaCoA with P2Y1. On the other hand, the 
antiplatelet action of PaCoA at platelet P2Y1 receptors, if found 
to be relevant in vivo, may suggest the use of PaCoA as a lead 
compound for the design of more potent compounds that can 
also bind and act as antagonists at P2Y1 receptors in platelets 
and exert this antithrombotic activity observed with PaCoA. 
 
In addition to the acyl-CoAs, another endogenous nucleotide 
derivative studied in this project was NAD. NAD is an essential 
coenzyme found in all cells. Intracellularly, NAD acts as an 
essential co-enzyme for the transfer of electrons in redox 
reactions and is also involved in other cellular processes such as 
acting as a substrate for several enzymes. Normally, the 
concentration of NAD depends on the balance between its 
release from cells and its enzymatic degradation. In human 
plasma, and in other extracellular fluids, the NAD concentration 
was reported to be in the range of 40 - 100 nM (Bruzzone et al., 
2001, De Flora et al., 2004). In certain pathophysiological states, 
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such as inflammation, levels of NAD were reported to be 
significantly higher in some tissues compared to those in plasma 
(Smyth et al., 2004, Krebs et al., 2005, Scheuplein et al., 2009). 
Extracellularly, NAD can elicit functional responses by binding 
to specific receptors, namely purinergic receptors and this may 
occur by direct actions of NAD or may involve metabolites 
generated by NAD hydrolysis, or through release of purines. 
NAD has been reported to have different signalling cascades and 
outcomes according to both cell type and environment; for 
example, in human granulocytes, NAD activates P2Y11 receptor 
and results in cell activation (Moreschi et al., 2006). On the 
other hand, in gastrointestinal myocytes, NAD also activates 
P2Y11 receptors and results in cell inhibition (Mutafova-
Yambolieva et al., 2007). In the present study, NAD was found to 
act as an agonist at P2X receptors in PMA evoking 
vasoconstriction and an agonist at A2A receptors in RTA and PCA 
eliciting vasorelaxation (Chapter Five). It is tempting to speculate 
that the actions of NAD at A2A receptors are via adenosine 
generated from hydrolysis of NAD. 
 
Enzymes such as CD38 can hydrolyse NAD and generate several 
metabolites such as ADPR and nicotinamide which may also be 
hydrolysed further into adenosine monophosphate and then 
converted to adenosine (Chapter Five). These metabolites and 
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metabolizing enzymes may also exert some potential 
extracellular and intracellular effects; for example adenosine can 
either bind to A2A receptors or it can be used to reconstitute the 
intracellular nucleotide pool. So the hydrolysis of NAD can 
recycle these metabolites and also regulate signals mediated by 
purine receptors. The possibility that the extracellular pool of 
NAD and its metabolites may affect some intracellular functions 
has been explored in chronic lymphocytic leukemia cells. It was 
suggested that this extracellular network of NAD and its 
metabolites and the modulation of this network by hydrolyzing 
enzymes may contribute to modifying the local environment, 
making it favorable to the neoplastic cells, and that exploring 
this field may change therapeutic strategies for the management 
of lymphocytic leukemia (Vaisitti et al., 2011). 
 
 
In this study, it was not determined whether the NAD responses 
in PMA, mediated through P2X receptors, and in PCA and RTA, 
through A2A receptors, are a result of NAD acting directly at 
these receptors, through its metabolites or by evoking the 
release of nucleosides such as adenosine (Chapter Five). 
Although the reported plasma levels of NAD described above are 
lower than the range of concentrations we have used, levels of 
NAD resulting from cell disruption in some pathophysiological 
conditions may rise to relatively high levels. The action of NAD 
in PMA and PCA gives an indication of a probable application of 
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this compound; the relaxatory response in coronary arteries and 
the contraction in the mesenteric arteries may give a hint that 
these compounds may be used as a lead for compounds that 
may be used in the management of cardiovascular diseases such 
as angina and narrowing of coronary arteries.  
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